KR102621315B1 - Composition for coating medical devices - Google Patents
Composition for coating medical devices Download PDFInfo
- Publication number
- KR102621315B1 KR102621315B1 KR1020210088341A KR20210088341A KR102621315B1 KR 102621315 B1 KR102621315 B1 KR 102621315B1 KR 1020210088341 A KR1020210088341 A KR 1020210088341A KR 20210088341 A KR20210088341 A KR 20210088341A KR 102621315 B1 KR102621315 B1 KR 102621315B1
- Authority
- KR
- South Korea
- Prior art keywords
- coating
- medical
- stent
- composition
- solvent
- Prior art date
Links
- 238000000576 coating method Methods 0.000 title claims abstract description 99
- 239000011248 coating agent Substances 0.000 title claims abstract description 97
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 239000000049 pigment Substances 0.000 claims abstract description 22
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 claims description 84
- 229960000907 methylthioninium chloride Drugs 0.000 claims description 84
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 78
- 229950003937 tolonium Drugs 0.000 claims description 76
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 claims description 76
- 239000002904 solvent Substances 0.000 claims description 63
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 48
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 30
- OYINILBBZAQBEV-UWJYYQICSA-N (17s,18s)-18-(2-carboxyethyl)-20-(carboxymethyl)-12-ethenyl-7-ethyl-3,8,13,17-tetramethyl-17,18,22,23-tetrahydroporphyrin-2-carboxylic acid Chemical compound N1C2=C(C)C(C=C)=C1C=C(N1)C(C)=C(CC)C1=CC(C(C)=C1C(O)=O)=NC1=C(CC(O)=O)C([C@@H](CCC(O)=O)[C@@H]1C)=NC1=C2 OYINILBBZAQBEV-UWJYYQICSA-N 0.000 claims description 24
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 24
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 24
- 239000008096 xylene Substances 0.000 claims description 24
- 229960003569 hematoporphyrin Drugs 0.000 claims description 23
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical compound CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 21
- 229920001296 polysiloxane Polymers 0.000 claims description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- 229920000642 polymer Polymers 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 10
- 229960004657 indocyanine green Drugs 0.000 claims description 10
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 claims description 10
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 claims description 9
- 239000004094 surface-active agent Substances 0.000 claims description 8
- 239000012046 mixed solvent Substances 0.000 claims description 7
- -1 tetrahydropuran Natural products 0.000 claims description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- 239000008213 purified water Substances 0.000 claims description 3
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims 1
- 239000001301 oxygen Substances 0.000 abstract description 39
- 229910052760 oxygen Inorganic materials 0.000 abstract description 39
- 238000002428 photodynamic therapy Methods 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 7
- 230000014759 maintenance of location Effects 0.000 abstract description 3
- 231100000419 toxicity Toxicity 0.000 abstract description 2
- 230000001988 toxicity Effects 0.000 abstract description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 36
- 239000000243 solution Substances 0.000 description 28
- 239000000975 dye Substances 0.000 description 27
- 239000004814 polyurethane Substances 0.000 description 20
- 229920002635 polyurethane Polymers 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 19
- 238000005063 solubilization Methods 0.000 description 18
- 230000007928 solubilization Effects 0.000 description 18
- 239000000463 material Substances 0.000 description 17
- 239000007850 fluorescent dye Substances 0.000 description 15
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 14
- 238000004090 dissolution Methods 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 238000011503 in vivo imaging Methods 0.000 description 9
- 239000003504 photosensitizing agent Substances 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 238000012790 confirmation Methods 0.000 description 6
- 239000008055 phosphate buffer solution Substances 0.000 description 6
- 229920001983 poloxamer Polymers 0.000 description 6
- 230000030833 cell death Effects 0.000 description 5
- 238000003618 dip coating Methods 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 239000010408 film Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 208000037062 Polyps Diseases 0.000 description 4
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 4
- HUVXQFBFIFIDDU-UHFFFAOYSA-N aluminum phthalocyanine Chemical compound [Al+3].C12=CC=CC=C2C(N=C2[N-]C(C3=CC=CC=C32)=N2)=NC1=NC([C]1C=CC=CC1=1)=NC=1N=C1[C]3C=CC=CC3=C2[N-]1 HUVXQFBFIFIDDU-UHFFFAOYSA-N 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 229940008099 dimethicone Drugs 0.000 description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 description 3
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 3
- 238000001839 endoscopy Methods 0.000 description 3
- 238000002073 fluorescence micrograph Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 229920006268 silicone film Polymers 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- PLPFBVXTEJUIIT-UHFFFAOYSA-N 1,2-dimethylanthracene Chemical compound C1=CC=CC2=CC3=C(C)C(C)=CC=C3C=C21 PLPFBVXTEJUIIT-UHFFFAOYSA-N 0.000 description 2
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010034972 Photosensitivity reaction Diseases 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 208000007578 phototoxic dermatitis Diseases 0.000 description 2
- 231100000018 phototoxicity Toxicity 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 150000004032 porphyrins Chemical class 0.000 description 2
- 238000002407 reforming Methods 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- IICCLYANAQEHCI-UHFFFAOYSA-N 4,5,6,7-tetrachloro-3',6'-dihydroxy-2',4',5',7'-tetraiodospiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 IICCLYANAQEHCI-UHFFFAOYSA-N 0.000 description 1
- JTGMTYWYUZDRBK-UHFFFAOYSA-N 9,10-dimethylanthracene Chemical compound C1=CC=C2C(C)=C(C=CC=C3)C3=C(C)C2=C1 JTGMTYWYUZDRBK-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229910000684 Cobalt-chrome Inorganic materials 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 206010061825 Duodenal neoplasm Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010054184 Small intestine carcinoma Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002334 Spandex Polymers 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- NRTOMJZYCJJWKI-UHFFFAOYSA-N Titanium nitride Chemical compound [Ti]#N NRTOMJZYCJJWKI-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- BHPNXACHQYJJJS-UHFFFAOYSA-N bacteriochlorin Chemical compound N1C(C=C2N=C(C=C3NC(=C4)C=C3)CC2)=CC=C1C=C1CCC4=N1 BHPNXACHQYJJJS-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000002046 chromoendoscopy Methods 0.000 description 1
- 239000010952 cobalt-chrome Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 201000000312 duodenum cancer Diseases 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- LKKPNUDVOYAOBB-UHFFFAOYSA-N naphthalocyanine Chemical compound N1C(N=C2C3=CC4=CC=CC=C4C=C3C(N=C3C4=CC5=CC=CC=C5C=C4C(=N4)N3)=N2)=C(C=C2C(C=CC=C2)=C2)C2=C1N=C1C2=CC3=CC=CC=C3C=C2C4=N1 LKKPNUDVOYAOBB-UHFFFAOYSA-N 0.000 description 1
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 1
- 229910001000 nickel titanium Inorganic materials 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000011941 photocatalyst Substances 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930187593 rose bengal Natural products 0.000 description 1
- 229940081623 rose bengal Drugs 0.000 description 1
- STRXNPAVPKGJQR-UHFFFAOYSA-N rose bengal A Natural products O1C(=O)C(C(=CC=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 STRXNPAVPKGJQR-UHFFFAOYSA-N 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000004759 spandex Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/006—Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
- A61N5/0603—Apparatus for use inside the body for treatment of body cavities
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/442—Colorants, dyes
Abstract
본 발명은 의료용으로 사용되고 있는 색소를 포함하는 의료기기 코팅용 조성물에 관한 것으로 상기 조성물을 사용하면 의료용 색소를 의료기기 표면에 고르게 분산시킬 수 있어 의료용 색소의 유지 기간이 현저히 증가하고, 활성산소 생성 효과 또한 우수하므로 광역학 치료 효과를 극대화시킬 수 있으며, 의료기기에서 유실된 색소의 체내 순환에 따른 독성에 관한 우려를 해소할 수 있다.The present invention relates to a composition for coating medical devices containing a dye used for medical purposes. Using the composition allows the medical dye to be evenly dispersed on the surface of the medical device, thereby significantly increasing the retention period of the medical dye and producing an active oxygen radical effect. In addition, because it is excellent, it can maximize the effect of photodynamic therapy and resolve concerns about the toxicity of pigment lost from medical devices when it circulates in the body.
Description
본 발명은 의료용으로 사용되고 있는 색소를 포함하는 의료기기 코팅용 조성물에 관한 것이다.The present invention relates to a composition for coating medical devices containing a pigment used for medical purposes.
광역학 치료(photodynamic therapy, PDT)는 광민감성 소재인 광감각제 (photosensitizer)를 이용한 의학적 치료방법이다. 광감각제는 특정 파장의 레이저를 조사하면 주변에 있는 산소를 통해 화학적 반응을 통해 활성산소를 형성하고, 주변 세포들을 산화 스트레스에 의해 일시적인 교란을 주거나 사멸을 일으킨다. 광역학 치료는 주로 암을 치료하기 위한 목적으로 많은 선행연구가 이루어졌으나, 바이러스 및 세균 등의 조절하고자 하는 생물체에 모두 접목할 수 있다. 따라서, 암뿐만 아니라 다양한 질병에 접목 가능한 치료방법이다. 위장관에 광역학 치료를 적용하기 위해서는 먼저 광감각제가 살포되어야 한다. 하지만, 복용 및 살포된 광감각제는 체액의 흐름에 의해 빠른 시간 내에 흘러내려가 생체내 이용률이 매우 낮다는 한계점이 존재한다.Photodynamic therapy (PDT) is a medical treatment method using photosensitizer, a light-sensitive material. When a photosensitizer is irradiated with a laser of a specific wavelength, it forms active oxygen through a chemical reaction with oxygen in the surrounding area, causing temporary disturbance or death of surrounding cells due to oxidative stress. A lot of prior research has been done on photodynamic therapy, mainly for the purpose of treating cancer, but it can be applied to all organisms to be controlled, such as viruses and bacteria. Therefore, it is a treatment method that can be applied not only to cancer but also to various diseases. To apply photodynamic therapy to the gastrointestinal tract, a photosensitizer must first be sprayed. However, the photosensitizer taken and sprayed has a limitation in that it quickly flows out due to the flow of body fluids and its bioavailability is very low.
또한, 임상에서 사용되고 있는 광감각제인 포르피린계 화합물, 클로린계 화합물, 박테리오클로린계 화합물, 프탈로시아닌계 화합물, 나프탈로시아닌계 화합물 및 5-아미노레블린 에스테르계 화합물 등은 비교적 고가의 약물이며, 난용성 물질로 여러 가지 응용에 제한점을 지닌다. 아울러 상기 광감각제를 이용한 수많은 연구가 진행되었지만, 임상 사례가 비교적 부족하며 국내 식품의약품안전처에서 허가 받은 약물은 포르피린계 화합물 단 한가지이다. In addition, photosensitizers used clinically, such as porphyrin-based compounds, chlorine-based compounds, bacteriochlorin-based compounds, phthalocyanine-based compounds, naphthalocyanine-based compounds, and 5-aminolevlin ester-based compounds, are relatively expensive drugs and poorly soluble substances. This has limitations in many applications. In addition, although numerous studies have been conducted using the above photosensitizer, clinical cases are relatively lacking, and the only drug approved by the Ministry of Food and Drug Safety in Korea is a porphyrin-based compound.
따라서, 광역학 치료를 효율적으로 수행하기 위해서는 광감각제의 제형을 변화시켜 단점을 개선하거나, 광감각제 이외에 다른 물질을 사용하거나 광역학 치료의 시술법을 변화시키는 등의 방법이 필요하다.Therefore, in order to perform photodynamic therapy efficiently, methods such as improving the shortcomings by changing the formulation of the photosensitizer, using materials other than the photosensitizer, or changing the photodynamic treatment method are needed.
본 발명은 상기한 종래 기술의 문제점을 해결하고자 한 것으로 생체내 이용률이 낮은 광감각제 대신 색소 내시경이나 세포 및 조직 염색에 이용되는 색소를 광역학 치료에 이용할 수 있는 방법을 연구하였다. 구체적으로 내시경용 색소를 광역학 치료에 사용되는 스텐트에 코팅할 수 있는 방법을 연구하였고, 코팅 용매에서 가용성이 낮은 내시경용 색소를 혼화 용매에 먼저 분산시킨 후 코팅 용매 및 의료기기 코팅용 고분자와 혼합하여 스텐트에 코팅시키면 색소를 스텐트 표면에 고르게 코팅할 수 있음을 확인하였다.The present invention was intended to solve the problems of the prior art described above, and studied a method of using pigments used in dye endoscopy or cell and tissue staining in photodynamic therapy instead of photosensitizers with low bioavailability. Specifically, we studied a method of coating endoscopic dyes on stents used in photodynamic therapy. Endoscopic dyes, which have low solubility in the coating solvent, were first dispersed in a miscible solvent and then mixed with the coating solvent and polymer for coating medical devices. It was confirmed that when coated on a stent, the dye could be evenly coated on the stent surface.
따라서, 본 발명의 목적은 내시경용 색소 및 내시경용 색소가 분산되는 혼화 용매를 포함하는 의료기기 코팅용 조성물과 상기 조성물로 코팅된 스텐트를 제공하는 것이다.Therefore, the purpose of the present invention is to provide a composition for coating a medical device containing an endoscopic dye and a miscible solvent in which the endoscopic dye is dispersed, and a stent coated with the composition.
상기 목적을 달성하기 위하여, 본 발명의 일 양상은 의료용 색소 및 상기 의료용 색소가 분산되는 혼화 용매를 포함하는 의료기기 코팅용 조성물을 제공한다.In order to achieve the above object, one aspect of the present invention provides a composition for coating a medical device including a medical dye and a miscible solvent in which the medical dye is dispersed.
본 명세서에 사용된 용어, "의료용 색소"는 현재 의료계에서 색소 내시경, 조직 염색 등에 사용되고 있는 안정성이 입증된 색소로서 빛을 조사하면 활성산소를 생성하는 색소를 말한다.As used herein, the term “medical pigment” refers to a pigment that has proven stability and is currently used in the medical field for color endoscopy, tissue staining, etc. and that generates active oxygen when irradiated with light.
본 발명에서, 상기 의료용 색소는 혼화 용매 100중량부에 1 내지 40중량부로 포함될 수 있으며, 보다 구체적으로는 혼화 용매 100중량부 당 5 내지 30 중량부로 포함될 수 있다. 본 발명의 일 구체예에 따르면, 혼화용매 1 ㎖ 당 내시경용 색소를 10 내지 20 ㎎ 포함할 수 있으며, 의료기기 코팅용 조성물에는 내시경용 색소를 최종 농도 0.1 내지 1.0 ㎎/㎖로 포함할 수 있다.In the present invention, the medical pigment may be included in an amount of 1 to 40 parts by weight per 100 parts by weight of the miscible solvent, and more specifically, it may be included in an amount of 5 to 30 parts by weight per 100 parts by weight of the miscible solvent. According to one embodiment of the present invention, 10 to 20 mg of an endoscopic dye may be included per 1 ml of the mixed solvent, and the composition for coating a medical device may contain an endoscopic dye at a final concentration of 0.1 to 1.0 mg/ml. .
본 발명의 일 구체예에 따르면, 활성산소 생성량은 의료기기에 코팅된 내시경용 색소의 농도와 비례하여 증가하나 일정 농도 이후에는 오히려 소실되거나 더 이상 증가하지 않는 포화상태를 보인다.According to one embodiment of the present invention, the amount of active oxygen produced increases in proportion to the concentration of the endoscopic dye coated on the medical device, but after a certain concentration, it disappears or reaches a saturation state where it no longer increases.
본 발명의 일 구체예에서 상기 의료용 색소는 메틸렌블루 (methylen blue), 톨루이딘블루 (toluidin blue), 인도시아닌 그린 (indocyanine green), 프탈로시아닌 (phthalocyanine), 에리스로신 (erythrosin), 로즈벵갈 (rose bengal), 클로린e6 및 헤마토포르피린으로 이루어진 군에서 선택될 수 있다.In one embodiment of the present invention, the medical pigment is methylen blue, toluidin blue, indocyanine green, phthalocyanine, erythrosin, and rose bengal. ), chlorine e6, and hematoporphyrin.
메틸렌블루는 강력한 양이온성 광촉매로 파장 670 ㎚ 부근의 빛을 가장 잘 흡수하며, 흡수량과 최대 흡수점은 메틸렌블루의 고차 응집체 물질 흡착 여부와 농도 등에 따라 결정된다. 600 ㎚ 파장의 빛을 받았을 때 활성산소를 형성하므로 광역학 치료에 사용될 수 있으며, 가격 또한 비교적 저렴하다. 메틸렌블루는 내시경 용종 제거술에서 생리식염수, 에피네프린과 함께 투여되며 용종 주위의 점막 염색을 위해 사용된다. 용종을 제거할 때 주변 조직이 함께 제거되는데, 경우에 따라 용종 제거의 이득이 더 큰지 조직 손상으로 인한 위험이 더 큰지 판단할 수 있게 한다. 또한, 색소 내시경 (chromoendoscopy)에서 염료로 사용되어 소화관의 구분과 이형성 세포 또는 암 발병 가능 세포를 분별하는 용도로 쓰인다. Methylene blue is a strong cationic photocatalyst that best absorbs light around a wavelength of 670 nm, and the absorption amount and maximum absorption point are determined by the adsorption and concentration of higher-order aggregate substances of methylene blue. Since it forms active oxygen when exposed to light with a wavelength of 600 nm, it can be used in photodynamic therapy and is also relatively inexpensive. Methylene blue is administered along with saline and epinephrine during endoscopic polyp removal and is used to stain the mucous membrane around the polyp. When a polyp is removed, the surrounding tissue is also removed, and in some cases, it is possible to determine whether the benefit of polyp removal is greater or the risk of tissue damage is greater. Additionally, it is used as a dye in chromoendoscopy to distinguish the digestive tract and identify dysplastic cells or cells that can develop cancer.
메틸렌블루와 같은 색소류는 매우 낮은 농도에서도 선명한 색을 나타내어 의료기기에 코팅 시 생체 내 조직과 색상이 대비되므로 의료기기의 조작을 용이하게 할 수 있다.Pigments such as methylene blue display vivid colors even at very low concentrations, so when coated on medical devices, the color contrasts with in vivo tissue, making it easier to operate medical devices.
본 발명의 일 구체예에서, 상기 클로린e6 및 헤마토포르피린은 친수성으로 개질화될 수 있다. 보다 구체적으로 클로린e6는 메톡시폴리에틸렌글리콜2K, - 메톡시폴리에틸렌글리콜5K, 메톡시폴리에틸렌글리콜30K, 플루로닉F68, 플루로닉F127과 접합되어 친수성이 증가할 수 있고, 헤마토포르피린은 플루로닉F127과 접합될 수 있다.In one embodiment of the present invention, chlorine e6 and hematoporphyrin may be modified to be hydrophilic. More specifically, chlorine e6 can be conjugated with methoxypolyethylene glycol 2K, - methoxypolyethylene glycol 5K, methoxypolyethylene glycol 30K, Pluronic F68, and Pluronic F127 to increase hydrophilicity, and hematoporphyrin can be conjugated with fluorine. Can be conjugated with nick F127.
본 명세서에 사용된 용어, "혼화 용매"는 의료용 색소가 코팅 용매와 잘 혼합될 수 있도록 의료용 색소를 분산시키는 용매를 말한다.As used herein, the term “miscible solvent” refers to a solvent that disperses the medical pigment so that the medical pigment can be well mixed with the coating solvent.
본 발명자들은 상기 의료용 색소를 의료기기 코팅에 사용되는 용매(코팅 용매)인 자일렌 및 테트라하이드로푸란에 용해시켰고, 메틸렌블루 및 톨루이딘블루 모두 거의 용해되지 않는 것을 확인하였다 (도 1). 이에 가용성(용해도)을 높이기 위해 다양한 혼화 용매에 의료용 색소를 분산시키고, 이를 다시 코팅 용매와 혼합하면 의료용 색소의 가용성이 증가하는 것을 확인하였다 (도 2 내지 9).The present inventors dissolved the medical dye in xylene and tetrahydrofuran, which are solvents used for coating medical devices (coating solvents), and confirmed that both methylene blue and toluidine blue were almost insoluble (Figure 1). Accordingly, it was confirmed that the solubility of the medical pigment increased when the medical pigment was dispersed in various miscible solvents to increase solubility and then mixed with the coating solvent (FIGS. 2 to 9).
본 발명에서, 상기 혼화 용매는 메탄올 (methanol), 디메틸설폭사이드 (dimethylsulfoxide), 디메틸포름아미드 (dimethylformamide), 정제수, 에틸아세테이트 (ethyl acetate), 테트라하이드로푸란 (tetrahydropuran) 및 에탄올 (ethanol)로 이루어진 군에서 선택될 수 있다.In the present invention, the mixed solvent is a group consisting of methanol, dimethylsulfoxide, dimethylformamide, purified water, ethyl acetate, tetrahydropuran, and ethanol. can be selected from
본 발명의 일 구체예에서, 상기 혼화 용매는 의료용 색소 및/또는 코팅 용매에 따라 달라질 수 있다. 예를 들어 내시경용 색소로 메틸렌블루 또는 톨루이딘블루를 사용하면 혼화 용매는 메탄올일 수 있다. 또한, 내시경용 색소로 인도시아닌 그린을 사용하면 혼화 용매는 코팅 용매에 따라 달라질 수 있으며, 코팅 용매가 자일렌이면 혼화 용매는 메탄올, 코팅 용매가 테트라하이드로푸란이면 혼화 용매는 디메틸포름아미드일 수 있다. 내시경용 색소가 프탈로시아닌일 때 혼화 용매는 코팅 용매가 자일렌이면 디메틸설폭사이드 또는 디메틸포름아미드일 수 있고, 코팅 용매가 테트라하이드로푸란이면 정제수, 에틸 아세테이트 또는 에탄올일 수 있다.In one embodiment of the present invention, the mixing solvent may vary depending on the medical pigment and/or coating solvent. For example, when methylene blue or toluidine blue is used as an endoscope dye, the mixing solvent may be methanol. In addition, when indocyanine green is used as an endoscopic dye, the mixing solvent may vary depending on the coating solvent. If the coating solvent is xylene, the mixing solvent may be methanol, and if the coating solvent is tetrahydrofuran, the mixing solvent may be dimethylformamide. there is. When the endoscopic dye is phthalocyanine, the mixing solvent may be dimethyl sulfoxide or dimethylformamide if the coating solvent is xylene, and may be purified water, ethyl acetate, or ethanol if the coating solvent is tetrahydrofuran.
본 발명자들은 계면활성제가 첨가되거나 첨가되지 않은 혼화 용매에 의료용 색소를 분산시키고, 이를 코팅 용매 및 의료기기 코팅용 고분자와 혼합하여 스텐트에 코팅시키면 의료용 색소가 의료기기 표면에 균일하게 코팅되고, 색소의 유실률 또한 감소하는 것을 확인하였다 (도 13, 18 및 19).The present inventors disperse the medical dye in a mixed solvent with or without added surfactant, mix it with a coating solvent and a polymer for coating medical devices, and coat the stent, so that the medical dye is uniformly coated on the surface of the medical device, and the dye's It was confirmed that the loss rate also decreased (Figures 13, 18, and 19).
따라서, 상기 의료기기 코팅용 조성물은 계면활성제, 코팅 용매 및 의료기기 코팅용 고분자를 추가로 포함할 수 있다.Therefore, the composition for coating medical devices may further include a surfactant, a coating solvent, and a polymer for coating medical devices.
본 명세서에 사용된 용어, "코팅 용매"는 의료기기 코팅용 고분자를 분산시키는 데 사용되는 용매이며, 의료기기에 고분자를 코팅시킨 후에는 휘발시켜 제거한다.As used herein, the term “coating solvent” is a solvent used to disperse polymers for coating medical devices, and is removed by volatilization after coating the polymers on medical devices.
본 발명에서, 상기 코팅 용매는 자일렌 (xylene), 테트라하이드로푸란 (tetrahydrofuran), 다이클로로메테인 (dichloromethane), 부틸 알코올 (butanol), 나프타 (naphtha), 헥세인 (hexane), 헵테인 (heptanes) 및 아세톤 (acetone)으로 이루어진 군에서 선택될 수 있다. 본 발명의 일 구체예에 따르면, 상기 코팅 용매는 자일렌 또는 테트라하이드로푸란일 수 있다.In the present invention, the coating solvent is xylene, tetrahydrofuran, dichloromethane, butanol, naphtha, hexane, and heptane. ) and acetone. According to one embodiment of the present invention, the coating solvent may be xylene or tetrahydrofuran.
본 발명에서, 상기 의료기기 코팅용 고분자는 실리콘 혼화물, 메티콘 (methicone), 디메티콘 (dimethicone), 사이클로메티콘 (cyclomethicone), 폴리실리콘 (polysilicone), 사이클로펜타실록산 (cyclopentasiloxane) 디메티콘 코폴리울 (dimethicone copolyol) 및 이의 유도체, 디메티코놀(dimethiconol) 및 이의 유도체, 폴리우레탄 (polyurethane) 및 이의 유도체, 티타니움나이트라이드 옥사이드(titanium nitride oxide), 카보필름 (carbofilm), 나일론 (nylon), 및 테프론 (teflon)으로 이루어진 군에서 선택될 수 있다. 본 발명의 일 구체예에 따르면, 상기 의료기기 코팅용 고분자는 실리콘 혼화물 또는 폴리우레탄일 수 있다.In the present invention, the polymer for coating medical devices is a silicone mixture, methicone, dimethicone, cyclomethicone, polysilicone, cyclopentasiloxane, and dimethicone copolymer. Wool (dimethicone copolyol) and its derivatives, dimethiconol and its derivatives, polyurethane and its derivatives, titanium nitride oxide, carbofilm, nylon, and It may be selected from the group consisting of Teflon. According to one embodiment of the present invention, the polymer for coating medical devices may be a silicone mixture or polyurethane.
본 발명의 일 구체예에 따르면, 상기 의료기기 코팅용 조성물은 조성물 100 중량부에 대하여 내시경용 색소 0.001 내지 0.02 중량부, 혼화용매 0.5 내지 10 중량부, 의료기기 코팅용 고분자 7 내지 85 중량부, 코팅용매 0 내지 80 중량부 및 계면활성제 0 내지 10 중량부를 포함할 수 있다.According to one embodiment of the present invention, the composition for coating medical devices includes 0.001 to 0.02 parts by weight of an endoscopic dye, 0.5 to 10 parts by weight of a mixed solvent, 7 to 85 parts by weight of a polymer for coating medical devices, based on 100 parts by weight of the composition. It may include 0 to 80 parts by weight of a coating solvent and 0 to 10 parts by weight of a surfactant.
본 발명에서, 상기 의료기기 코팅용 조성물은 스테인리스 스틸 (stainless steel), 코발트-크롬 합금 (cobalt chrome), 탄탈륨 (tantalum), 니티놀 (nitinol) 및 금 (gold)으로 이루어진 군 중에서 선택되는 재질로 이루어진 의료기기에 적용될 수 있다. 본 발명의 일 구체예에 따르면, 상기 의료기기는 스텐트일 수 있으며, 비혈관 및 혈관계 스텐트를 포함할 수 있다.In the present invention, the composition for coating medical devices is made of a material selected from the group consisting of stainless steel, cobalt-chrome alloy, tantalum, nitinol, and gold. It can be applied to medical devices. According to one embodiment of the present invention, the medical device may be a stent and may include non-vascular and vascular stents.
본 발명자들은 상기 메틸렌블루 또는 톨루이딘 블루를 포함하는 의료기기 코팅용 조성물로 스텐트를 코팅한 후 코팅된 색소의 양을 확인하였다. 그 결과, 색소의 가용성을 개선시키지 않고 코팅시킨 스텐트와 비교하여 가용성을 개선하여 코팅시킨 스텐트에 메틸렌블루 또는 톨루이딘 블루가 더 많이 코팅된 것을 확인하였다 (도 14). 구체적으로 가용성 개선 전과 비교하여 단위 면적당 코팅되는 색소의 양이 약 4배 내지 5배 증가하였다.The present inventors coated a stent with the composition for coating medical devices containing the methylene blue or toluidine blue and then checked the amount of the coated dye. As a result, it was confirmed that more methylene blue or toluidine blue was coated on the stent coated with improved solubility compared to the stent coated without improving the solubility of the dye (FIG. 14). Specifically, compared to before the solubility was improved, the amount of pigment coated per unit area increased by about 4 to 5 times.
본 발명의 일 구체예에 따르면, 상기 의료기기 코팅용 조성물은 의료기기 면적당 단위질량비가 0.1 내지 50 ㎍/㎠ 또는 의료기기 무게당 단위 질량비가 0.01 내지 5 ㎍/㎖일 수 있다.According to one embodiment of the present invention, the composition for coating a medical device may have a unit mass ratio per area of the medical device of 0.1 to 50 ㎍/㎠ or a unit mass ratio per weight of the medical device of 0.01 to 5 ㎍/㎖.
본 발명의 다른 양상은 의료기기 코팅용 조성물로 코팅된 광응답성 스텐트를 제공한다. 상기 광응답성 스텐트는 의료용 색소가 표면에 균일하게 도포되어 있어 색소의 유지기간이 길고, 활성산소 생성능 또한 우수한 특성을 가진다. 활성산소는 위장암, 췌장암, 십이지장암 및 대장암 등의 암 치료뿐만 아니라 비만 및 대사질환을 치료하는 것을 목적으로 하는 의료기기에 응용 가능하다.Another aspect of the present invention provides a light-responsive stent coated with a composition for coating medical devices. The light-responsive stent has a medical dye uniformly applied to the surface, so the dye lasts for a long time and has excellent oxygen generation ability. Active oxygen can be applied to medical devices aimed at treating obesity and metabolic diseases as well as treating cancer such as gastrointestinal cancer, pancreatic cancer, duodenal cancer, and colon cancer.
본 발명에 따른 의료기기 코팅용 조성물은 의료용 색소를 의료기기 표면에 고르게 분산시킬 수 있어 의료용 색소의 유지 기간이 현저히 증가하고, 활성산소 생성 효과 또한 우수하므로 광역학 치료 효과를 극대화시킬 수 있으며, 의료기기에서 유실된 색소의 체내 순환에 따른 독성에 관한 우려를 해소할 수 있다.The composition for coating medical devices according to the present invention can evenly disperse medical pigments on the surface of medical devices, significantly increasing the retention period of medical pigments, and also has an excellent effect of generating active oxygen, thereby maximizing the photodynamic treatment effect and medical treatment. This can resolve concerns about the toxicity of pigment lost from the device as it circulates in the body.
도 1은 메틸렌블루 및 톨루이딘블루를 물, 자일렌 및 테트라하이드로푸란에 각각 용해시켜 가용성을 확인한 결과이다.
도 2는 메틸렌블루의 가용성을 개선하기 위해 다양한 혼화 용매에 용해시킨 후 용해 여부를 확인한 결과이다.
도 3은 메틸렌블루의 가용성을 개선하기 위해 다양한 혼화 용매에 용해시킨 후 용해 여부를 확인한 사진이다.
도 4는 톨루이딘블루의 가용성을 개선하기 위해 다양한 혼화 용매에 용해시킨 후 용해 여부를 확인한 결과이다.
도 5는 톨루이딘블루의 가용성을 개선하기 위해 다양한 혼화 용매에 용해시킨 후 용해 여부를 확인한 사진이다.
도 6은 인도시아닌 그린의 가용성을 개선하기 위해 다양한 혼화 용매에 용해시킨 후 용해 여부를 확인한 결과이다.
도 7은 인도시아닌 그린의 가용성을 개선하기 위해 다양한 혼화 용매에 용해시킨 후 용해 여부를 확인한 사진이다.
도 8은 알루미늄 프탈로시아닌의 가용성을 개선하기 위해 다양한 혼화 용매에 용해시킨 후 용해 여부를 확인한 결과이다.
도 9는 알루미늄 프탈로시아닌의 가용성을 개선하기 위해 다양한 혼화 용매에 용해시킨 후 용해 여부를 확인한 사진이다.
도 10은 메틸렌블루와 톨루이딘블루의 빛 조사 유무에 따른 활성산소 형성능을 확인한 결과이다.
도 11은 메틸렌블루와 톨루이딘블루의 빛 조사 유무에 따른 세포 광독성을 확인한 결과이다.
도 12는 가용성이 개선된 메틸렌블루 또는 톨루이딘블루를 코팅한 광응답성 스텐트의 광학 사진 및 형광 사진이다.
도 13은 가용성이 개선된 메틸렌블루 또는 톨루이딘블루를 코팅한 광응답성 스텐트의 표면 및 용출 시험 후 표면을 확인한 결과이다.
도 14는 가용성이 개선된 메틸렌블루 또는 톨루이딘블루를 코팅한 광응답성 스텐트에서 표면에 코팅된 형광 색소의 양을 정량한 결과이다.
도 15는 가용성이 개선된 메틸렌블루 또는 톨루이딘블루를 실리콘으로 코팅한 광응답성 스텐트에서 빛 조사에 따른 활성산소 형성능을 확인한 결과이다.
도 16은 가용성이 개선된 메틸렌블루 또는 톨루이딘블루를 폴리우레탄으로 코팅한 광응답성 스텐트에서 빛 조사에 따른 활성산소 형성능을 확인한 결과이다.
도 17은 가용성이 개선된 메틸렌블루 또는 톨루이딘블루를 코팅한 광응답성 스텐트에서 빛의 반복 조사에 따른 활성산소 형성능을 확인한 결과이다.
도 18은 가용성이 개선된 메틸렌블루 또는 톨루이딘블루를 실리콘으로 코팅한 광응답성 스텐트를 인산완충용액에 담근 후 시간에 따른 형광 색소 유실율을 확인한 결과이다.
도 19는 가용성이 개선된 메틸렌블루 또는 톨루이딘블루를 폴리우레탄으로 코팅한 광응답성 스텐트를 인산완충용액에 담근 후 시간에 따른 형광 색소 유실율을 확인한 결과이다.
도 20은 가용성이 개선된 메틸렌블루 또는 톨루이딘블루를 코팅한 광응답성 스텐트를 단일 세포층 위에 얹고, 빛을 조사하여 세포 사멸 유무를 확인한 결과이다.
도 21은 스텐트를 친수성으로 개질화된 클로린e6 또는 헤마토포르피린으로 코팅한 후 형광 현미경으로 코팅 여부를 확인한 결과이다.
도 22는 친수성으로 개질화된 클로린e6 또는 헤마토포르피린으로 코팅된 스텐트에서 빛의 세기에 따른 활성산소 형성능을 확인한 결과이다.
도 23은 친수성으로 개질화된 클로린e6 또는 헤마토포르피린으로 코팅된 스텐트의 시간에 따른 형광 색소 유실율을 확인한 결과이다.Figure 1 shows the results of confirming the solubility of methylene blue and toluidine blue by dissolving them in water, xylene, and tetrahydrofuran, respectively.
Figure 2 shows the results of checking whether methylene blue is dissolved in various miscible solvents to improve its solubility.
Figure 3 is a photograph showing the dissolution of methylene blue after dissolving it in various solvents to improve its solubility.
Figure 4 shows the results of checking whether toluidine blue is dissolved in various miscible solvents to improve its solubility.
Figure 5 is a photograph showing the dissolution of toluidine blue after dissolving it in various solvents to improve the solubility.
Figure 6 shows the results of checking whether indocyanine green is dissolved in various miscible solvents to improve its solubility.
Figure 7 is a photograph showing the dissolution of indocyanine green after dissolving it in various solvents to improve the solubility.
Figure 8 shows the results of confirming the dissolution of aluminum phthalocyanine after dissolving it in various miscible solvents to improve the solubility of aluminum phthalocyanine.
Figure 9 is a photograph showing dissolution of aluminum phthalocyanine after dissolving it in various solvents to improve the solubility of aluminum phthalocyanine.
Figure 10 shows the results of confirming the active oxygen forming ability of methylene blue and toluidine blue depending on the presence or absence of light irradiation.
Figure 11 shows the results of confirming cell phototoxicity according to the presence or absence of light irradiation of methylene blue and toluidine blue.
Figure 12 is an optical photograph and a fluorescence photograph of a light-responsive stent coated with methylene blue or toluidine blue with improved solubility.
Figure 13 shows the results of confirming the surface and dissolution test of a light-responsive stent coated with methylene blue or toluidine blue with improved solubility.
Figure 14 shows the results of quantifying the amount of fluorescent dye coated on the surface of a photoresponsive stent coated with methylene blue or toluidine blue with improved solubility.
Figure 15 shows the results of confirming the ability of active oxygen formation according to light irradiation in a photoresponsive stent coated with methylene blue or toluidine blue with improved solubility with silicone.
Figure 16 shows the results of confirming the ability to form active oxygen upon light irradiation in a photoresponsive stent coated with polyurethane with methylene blue or toluidine blue with improved solubility.
Figure 17 shows the results of confirming the ability to form active oxygen upon repeated irradiation of light in a photoresponsive stent coated with methylene blue or toluidine blue with improved solubility.
Figure 18 shows the results of confirming the loss rate of fluorescent dye over time after immersing a photoresponsive stent coated with methylene blue or toluidine blue with improved solubility with silicone in a phosphate buffer solution.
Figure 19 shows the results of confirming the loss rate of fluorescent dye over time after immersing a light-responsive stent coated with polyurethane with methylene blue or toluidine blue with improved solubility in a phosphate buffer solution.
Figure 20 shows the results of placing a photoresponsive stent coated with methylene blue or toluidine blue with improved solubility on a single cell layer and irradiating light to confirm the presence or absence of cell death.
Figure 21 shows the results of coating a stent with hydrophilically modified chlorine e6 or hematoporphyrin and then confirming the coating using a fluorescence microscope.
Figure 22 shows the results of confirming the oxygen radical forming ability according to the intensity of light in a stent coated with hydrophilic modified chlorine e6 or hematoporphyrin.
Figure 23 shows the results of confirming the fluorescent dye loss rate over time of a stent coated with hydrophilically modified chlorine e6 or hematoporphyrin.
이하 하나 이상의 구체예를 실시예를 통하여 보다 상세하게 설명한다. 그러나 이들 실시예는 하나 이상의 구체예를 예시적으로 설명하기 위한 것으로 본 발명의 범위가 이들 실시예에 한정되는 것은 아니다.Hereinafter, one or more specific examples will be described in more detail through examples. However, these examples are for illustrative purposes of one or more specific examples and the scope of the present invention is not limited to these examples.
실시예 1: 메틸렌블루 및 톨루이딘블루의 가용화 개선Example 1: Improved solubilization of methylene blue and toluidine blue
의료기기에 메틸렌블루 및 톨루이딘블루를 코팅하기 위해서는 이들 색소가 코팅 용매에 잘 용해되어야 한다. 따라서, 메틸렌블루 및 톨루이딘블루의 가용성을 확인하기 위해 의료기기 코팅에 자주 사용되는 물, 자일렌 및 테트라하이드로푸란 (tetrahydrofuran, THF)에 각각 용해시켰다. 그 결과, 메틸렌블루는 물에는 잘 용해되지만 자일렌과 THF에는 전혀 용해되지 않고, 톨루이딘블루는 물에는 잘 용해되지만 자일렌과 THF에서는 거의 용해되지 않는 것을 확인하였다 (도 1). 따라서, 다음과 같이 용해도를 개선하였다.In order to coat medical devices with methylene blue and toluidine blue, these pigments must be well dissolved in the coating solvent. Therefore, to check the solubility of methylene blue and toluidine blue, they were dissolved in water, xylene, and tetrahydrofuran (THF), which are frequently used for coating medical devices, respectively. As a result, it was confirmed that methylene blue was well soluble in water but not at all soluble in xylene and THF, and toluidine blue was well soluble in water but almost insoluble in xylene and THF (Figure 1). Therefore, solubility was improved as follows.
1-1. 자일렌에서의 가용화 개선1-1. Improved solubilization in xylene
메틸렌블루 또는 톨루이딘블루를 클로로포름, 아세톤, 에탄올, 아세토나이트릴, 이소프로필 알코올, 디메틸설폭사이드 (dimethyl sulfoxide, DMSO), 디메틸포름아미드(dimethylforamide) 및 메탄올에 1 ㎎/㎖의 농도로 각각 용해하고, 이의 용해 여부를 비교하였다. 용해되지 않으면 X 용해되면 O로 표기하였으며, 용해 여부는 틴들 효과를 통해 빛의 산란 여부로 판단하였다. 다양한 혼화 용매에 용해시킨 결과, 메틸렌블루 및 톨루이딘블루 모두 메탄올을 제외한 혼화 용매에서는 용해가 이루어지지 않았다. 또한, 톨루이딘블루는 메탄올에 용해되더라도 안정성이 떨어져 한 시간 후에 응집이 관찰되었다. 이에 메틸렌블루 또는 톨루이딘블루를 메탄올이 0.5 내지 20.0% 포함된 자일렌 1 ㎖에 0.1 ㎎/㎖로 용해하여 잘 혼화되는 범위를 확인하였고, 안정성이 떨어지면 계면활성제를 0.2 내지 1.0%로 보완하여 스텐트 코팅에 응용하였다 (도 2의 A, 도 3의 A, 도 4의 A 및 도 5의 A).Dissolve methylene blue or toluidine blue in chloroform, acetone, ethanol, acetonitrile, isopropyl alcohol, dimethyl sulfoxide (DMSO), dimethylformamide, and methanol at a concentration of 1 mg/ml, respectively. The dissolution was compared. If it is not dissolved, it is marked as As a result of dissolving in various mixed solvents, neither methylene blue nor toluidine blue was dissolved in mixed solvents except methanol. In addition, toluidine blue had poor stability even when dissolved in methanol, and aggregation was observed after one hour. Accordingly, methylene blue or toluidine blue was dissolved at 0.1 mg/ml in 1 ml of xylene containing 0.5 to 20.0% of methanol to check the range of good miscibility. If stability was poor, the surfactant was supplemented with 0.2 to 1.0% to coat the stent. It was applied (A in Figure 2, A in Figure 3, A in Figure 4, and A in Figure 5).
1-2. 테트라하이드로푸란에서의 가용화 개선1-2. Improved solubilization in tetrahydrofuran
메틸렌블루 또는 톨루이딘블루를 탈이온수, 에틸아세테이트, 에탄올, 디메틸 술폭시드, 디메틸포름아미드 및 메탄올에 1 ㎎/㎖의 농도로 용해하고 이의 용해 정도를 비교하였다. 용해되지 않으면 X 용해되면 O로 표기하였으며, 용해 여부는 틴들 효과를 통해 빛의 산란 여부로 판단하였다. 메틸렌블루 및 톨루이딘블루 모두 메탄올을 제외한 혼화 용매에서는 용해되지 않았다. 또한, 메틸렌블루는 메탄올에 용해되더라도 한 시간 이내로 안정성이 떨어져 응집이 관찰되었다. 이에 메틸렌블루 및 톨루이딘블루를 메탄올이 0.5 내지 20.0% 포함된 테트라하이드로푸란 1 ㎖에 0.1 ㎎/㎖로 용해하여 잘 혼화되는 범위를 확인하였으며, 분산성을 높이기 위해 트윈계 및 스판계 계면활성제를 보조제로 0.2 내지 1.0%로 사용하였다 (도 2의 B, 도 3의 B, 도 4의 B 및 도 5의 B).Methylene blue or toluidine blue was dissolved in deionized water, ethyl acetate, ethanol, dimethyl sulfoxide, dimethylformamide, and methanol at a concentration of 1 mg/ml, and the degree of dissolution was compared. If it is not dissolved, it is marked as Neither methylene blue nor toluidine blue was dissolved in miscible solvents other than methanol. In addition, even if methylene blue was dissolved in methanol, its stability decreased within one hour and aggregation was observed. Accordingly, methylene blue and toluidine blue were dissolved at 0.1 mg/ml in 1 ml of tetrahydrofuran containing 0.5 to 20.0% methanol to confirm the range of good miscibility, and Tween-based and spandex-based surfactants were added as auxiliaries to increase dispersibility. It was used at 0.2 to 1.0% (B in Figure 2, B in Figure 3, B in Figure 4, and B in Figure 5).
실시예 2: 인도시아닌그린 및 프탈로시아닌의 가용화 개선Example 2: Improvement of solubilization of indocyanine green and phthalocyanine
2-1. 자일렌에서의 가용화 개선2-1. Improved solubilization in xylene
인도시아닌그린 및 프탈로시아닌을 클로로폼, 아세톤, 에탄올, 아세토나이트릴, 이소프로필 알코올, 메탄올, 디메틸설폭사이드, 및 디메틸포름아미드에 1 ㎎/㎖의 농도로 용해하고, 이의 용해 여부를 비교하였다. 용해되지 않으면 X 용해되면 O로 표기하였으며, 용해 여부는 틴들 효과를 통해 빛의 산란 여부로 판단하였다. 메탄올을 제외한 용액에서는 인도시아닌그린 및 프탈로시아닌의 용해가 이루어지지 않았다. 인도시아닌그린 및 프탈로시아닌을 메탄올이 0.5 내지 20.0% 포함된 자일렌 1 ㎖에 0.1 ㎎/㎖로 용해하여 잘 혼화되는 범위를 확인하였으며, 이를 스텐트 코팅에 응용하고자 하였다 (도 6의 A, 도 7의 A, 도 8의 A 및 도 9의 A).Indocyanine green and phthalocyanine were dissolved in chloroform, acetone, ethanol, acetonitrile, isopropyl alcohol, methanol, dimethyl sulfoxide, and dimethylformamide at a concentration of 1 mg/ml, and their solubility was compared. If it is not dissolved, it is marked as Indocyanine green and phthalocyanine were not dissolved in solutions excluding methanol. Indocyanine green and phthalocyanine were dissolved at 0.1 mg/ml in 1 ml of xylene containing 0.5 to 20.0% methanol to confirm the range of good miscibility, and this was intended to be applied to stent coating (Figure 6A, Figure 7 A in , A in Figure 8 and A in Figure 9 ).
2-2. 테트라하이드로푸란에서의 가용화 개선2-2. Improved solubilization in tetrahydrofuran
인도시아닌그린 및 프탈로시아닌을 증류수, 에틸아세테이트, 에탄올, 디메틸설폭사이드, 디메틸포름아미드, 및 메탄올에 1 ㎎/㎖의 농도로 용해하고 이의 용해 정도를 비교하였다. 용해되지 않으면 X 용해되면 O로 표기하였으며, 용해 여부는 틴들 효과를 통해 빛의 산란 여부로 판단하였다. 디메틸포름아미드를 제외한 용매에서는 용해되지 않았으며, 디메틸포름아미드가 0.5 내지 20.0% 포함된 테트라하이드로푸란 1 ㎖에 0.1 ㎎/㎖로 용해하여 잘 혼화되는 범위를 확인하여 스텐트 코팅에 응용하고자 하였다 (도 6의 B, 도 7의 B, 도 8의 B 및 도 9의 B).Indocyanine green and phthalocyanine were dissolved in distilled water, ethyl acetate, ethanol, dimethyl sulfoxide, dimethylformamide, and methanol at a concentration of 1 mg/ml, and the degree of dissolution was compared. If it is not dissolved, it is marked as It was not soluble in solvents other than dimethylformamide, and was dissolved at 0.1 mg/ml in 1 ml of tetrahydrofuran containing 0.5 to 20.0% dimethylformamide to check the range of good miscibility and apply it to stent coating (Figure B in Figure 6, B in Figure 7, B in Figure 8 and B in Figure 9).
실시예 3: 메틸렌블루 또는 톨루이딘블루의 용해도가 개선되지 않은 광응답성 스텐트 제조Example 3: Preparation of a light-responsive stent without improved solubility of methylene blue or toluidine blue
3-1. 메틸렌블루 또는 톨루이딘블루와 실리콘 혼화물로 코팅된 광응답성 스텐트 제조3-1. Fabrication of light-responsive stents coated with methylene blue or toluidine blue and silicone mixture
메틸렌블루 또는 톨루이딘블루를 자일렌 1 ㎖에 2.5 ㎎/㎖ 농도로 교반을 통해 섞고, 실리콘 혼화물 4 ㎖을 첨가하여 24시간 교반을 통해 완전히 섞어주었다. 메틸렌블루 또는 톨루이딘블루가 포함된 실리콘 용액에 스텐트를 딥코팅 방식으로 코팅하고, 자일렌을 제거하기 위해 150℃에서 2시간 휘발하였다. 코팅막의 두께는 마이크로미터기를 사용하여 측정하였으며, 메틸렌블루 및 톨루이딘블루의 코팅 균일성은 형광 이미지 시스템(Fluorescence in vivo imaging system, Neoscience, Suwon, Korea)를 이용해 촬영했다. 스텐트 표면의 매끄러운 정도는 전자현미경을 통해 육안으로 관찰하였다.Methylene blue or toluidine blue was mixed with 1 ml of xylene at a concentration of 2.5 mg/ml by stirring, and 4 ml of silicone mixture was added and thoroughly mixed by stirring for 24 hours. The stent was coated with a silicone solution containing methylene blue or toluidine blue by dip coating, and volatilized at 150°C for 2 hours to remove xylene. The thickness of the coating film was measured using a micrometer, and the coating uniformity of methylene blue and toluidine blue was photographed using a fluorescence in vivo imaging system (Neoscience, Suwon, Korea). The smoothness of the stent surface was observed visually using an electron microscope.
3-2. 메틸렌블루 또는 톨루이딘블루와 폴리우레탄 용액으로 코팅된 광응답성 스텐트 제조3-2. Fabrication of light-responsive stents coated with methylene blue or toluidine blue and polyurethane solution
메틸렌블루 또는 톨루이딘블루를 테트라하이드로푸란 5 ㎖에 2.5 ㎎/㎖ 농도로 용해하고, 폴리우레탄 0.4 g을 첨가하여 24시간 교반을 통해 완전히 용해하였다. 메틸렌블루 또는 톨루이딘블루가 포함된 폴리우레탄 용액에 스텐트를 딥코팅 방식으로 코팅하고, 테트라하이드로푸란을 제거하기 위해 상온에서 6시간 휘발하였다. 코팅막의 두께는 마이크로미터기를 사용하여 측정하였으며, 메틸렌블루 및 톨루이딘블루의 코팅 균일성은 형광 이미지 시스템(Fluorescence in vivo imaging system, Neoscience, Suwon, Korea)를 이용해 촬영했다. 스텐트 표면의 매끄러운 정도는 전자현미경을 통해 육안으로 관찰하였다.Methylene blue or toluidine blue was dissolved in 5 ml of tetrahydrofuran at a concentration of 2.5 mg/ml, and 0.4 g of polyurethane was added and stirred for 24 hours to completely dissolve. The stent was coated in a polyurethane solution containing methylene blue or toluidine blue by dip coating, and volatilized at room temperature for 6 hours to remove tetrahydrofuran. The thickness of the coating film was measured using a micrometer, and the coating uniformity of methylene blue and toluidine blue was photographed using a fluorescence in vivo imaging system (Neoscience, Suwon, Korea). The smoothness of the stent surface was observed visually using an electron microscope.
실시예 4: 메틸렌블루 및 톨루이딘블루의 용해도가 개선된 광응답성 스텐트 제조Example 4: Preparation of a light-responsive stent with improved solubility of methylene blue and toluidine blue
4-1. 메틸렌블루 또는 톨루이딘블루와 실리콘 혼화물로 코팅된 광응답성 스텐트 제조4-1. Fabrication of light-responsive stents coated with methylene blue or toluidine blue and silicone mixture
메틸렌블루 또는 톨루이딘블루를 메탄올에 12.5 ㎎/㎖로 용해하고, 이를 자일렌 0.96 ㎖에 0.2 ㎖ 첨가하여 혼화시켰다. 실리콘 혼화물(Nusil, MED-6640) 3.84 ㎖ 및 메틸렌블루가 용해된 자일렌 1.16 ㎖을 혼화하여 내시경용 색소의 최종 농도가 0.5 ㎎/㎖인 스텐트 코팅용액을 제조하였다. 메틸렌블루 또는 톨루이딘블루가 포함된 스텐트 코팅용액에서 스텐트를 딥코팅 방식으로 코팅하였다. 자일렌 및 메탄올을 제거하기 위해 150℃에서 2시간 동안 휘발하였으며, 코팅막의 두께는 마이크로미터기를 사용하여 측정했다. 메틸렌블루 및 톨루이딘블루 코팅의 균일성은 형광 이미지 시스템(Fluorescence in vivo imaging system, Neoscience, Suwon, Korea)으로 촬영하고, 스텐트 표면의 매끄러운 정도는 전자현미경을 통해 육안으로 관찰하였다.Methylene blue or toluidine blue was dissolved in methanol at 12.5 mg/ml, and 0.2 ml of this was added to 0.96 ml of xylene and mixed. A stent coating solution with a final concentration of endoscope dye of 0.5 mg/ml was prepared by mixing 3.84 ml of silicone mixture (Nusil, MED-6640) and 1.16 ml of xylene in which methylene blue was dissolved. The stent was coated using a dip coating method in a stent coating solution containing methylene blue or toluidine blue. To remove xylene and methanol, it was volatilized at 150°C for 2 hours, and the thickness of the coating film was measured using a micrometer. The uniformity of the methylene blue and toluidine blue coatings was imaged with a fluorescence in vivo imaging system (Neoscience, Suwon, Korea), and the smoothness of the stent surface was observed with the naked eye through an electron microscope.
내시경용 색소의 최종 농도는 0.05, 0.10, 0.50 및 1.00 ㎎/㎖ 농도로 실험을 진행한 후 활성산소 생성량을 고려하여 최종적으로 0.5 ㎎/㎖로 결정하였다.The final concentration of the dye for endoscopy was tested at concentrations of 0.05, 0.10, 0.50, and 1.00 mg/ml, and was finally determined to be 0.5 mg/ml considering the amount of active oxygen produced.
4-2. 메틸렌블루 또는 톨루이딘블루와 폴리우레탄 용액으로 코팅된 광응답성 스텐트 제조4-2. Fabrication of light-responsive stents coated with methylene blue or toluidine blue and polyurethane solution
메틸렌블루 또는 톨루이딘블루를 메탄올에 50 ㎎/㎖로 용해하고 이 용액을 테트라하이드로푸란 4.95 ㎖에 0.05 ㎖씩 첨가하여 혼화한 뒤, 안정화를 높이기 위하여 0.7%의 트윈20, 트윈80, 또는 스판20을 첨가하였다. 메틸렌블루 또는 톨루이딘블루가 용해된 테트라하이드로푸란 5 ㎖과 폴리우레탄 400 ㎎을 혼화하여 스텐트 코팅용액을 제조하였다. 메틸렌블루 또는 톨루이딘블루가 포함된 폴리우레탄 용액에 스텐트를 딥코팅 방식으로 코팅하였다. 테트라하이드로푸란 및 메탄올을 제거하기 위해 25℃에서 6시간 휘발하였으며, 코팅막의 두께는 마이크로미터기를 사용하여 측정했다. 메틸렌블루 및 톨루이딘블루 코팅의 균일성은 형광 이미지 시스템(Fluorescence in vivo imaging system, Neoscience, Suwon, Korea)를 이용하여 촬영하고, 스텐트 표면의 매끄러운 정도를 전자현미경을 통해 육안으로 관찰하였다.Dissolve methylene blue or toluidine blue in methanol at 50 mg/ml, add 0.05 ml of this solution to 4.95 ml of tetrahydrofuran and mix, then add 0.7% of Tween 20, Tween 80, or Span 20 to increase stabilization. Added. A stent coating solution was prepared by mixing 5 ml of tetrahydrofuran in which methylene blue or toluidine blue was dissolved and 400 mg of polyurethane. The stent was coated with a polyurethane solution containing methylene blue or toluidine blue using a dip coating method. To remove tetrahydrofuran and methanol, it was volatilized at 25°C for 6 hours, and the thickness of the coating film was measured using a micrometer. The uniformity of the methylene blue and toluidine blue coatings was imaged using a fluorescence in vivo imaging system (Neoscience, Suwon, Korea), and the smoothness of the stent surface was observed with the naked eye through an electron microscope.
표 1에 본 실시예에서 제조한 가용성이 개선된 코팅 용액의 각 조성물 및 조성비를 기재하였다.Table 1 lists the composition and composition ratio of each coating solution with improved solubility prepared in this example.
실시예 5: 친수성 클로린e6 및 친수성 헤마토포르피린이 코팅된 광응답성 스텐트 제조Example 5: Preparation of a light-responsive stent coated with hydrophilic chlorine e6 and hydrophilic hematoporphyrin
친수성으로 개질화된 클로린e6(예를 들어, 메톡시폴리에틸렌글리콜2K-클로린e6, 메톡시폴리에틸렌글리콜5K-클로린e6, 메톡시폴리에틸렌글리콜30K-클로린e6, 플루로닉F68-클로린e6, 플루로닉F127-클로린e6 등) 및 개질화된 헤마토포르피린 (예를 들어, 플루로닉F127-헤마토포르피린)을 혼화 용매인 테트라하이드로푸란 (클로린e6) 또는 메탄올(헤마토포르피린)에 12.5 ㎎/㎖로 용해하고, 이 용액을 자일렌 0.96 ㎖에 0.2 ㎖ 첨가하여 혼화시켰다. 실리콘 혼화물 3.84 ㎖ 및 자일렌 1.16 ㎖을 혼화하여 스텐트 코팅용액을 제조하여 딥코팅 방식으로 스텐트 조각을 코팅하였다. 자일렌 및 테트라하이드로푸란(또는 메탄올)을 제거하기 위해 150℃에서 2시간 동안 휘발하였으며, 코팅막의 두께는 마이크로미터기로 측정했다. 코팅의 균일성은 형광 이미지 시스템(Fluorescence in vivo imaging system, Neoscience, Suwon, Korea)으로 촬영하였다.Hydrophilically modified chlorine e6 (e.g., methoxypolyethylene glycol 2K-chlorine e6, methoxypolyethylene glycol 5K-chlorine e6, methoxypolyethylene glycol 30K-chlorine e6, Pluronic F68-chlorine e6, Pluronic F127-chlorin e6, etc.) and modified hematoporphyrin (e.g., pluronic F127-hematoporphyrin) in tetrahydrofuran (chlorin e6) or methanol (hematoporphyrin) as a miscible solvent at 12.5 mg/ml. was dissolved, and 0.2 ml of this solution was added to 0.96 ml of xylene and mixed. A stent coating solution was prepared by mixing 3.84 ml of silicone mixture and 1.16 ml of xylene, and the stent pieces were coated by dip coating. To remove xylene and tetrahydrofuran (or methanol), it was volatilized at 150°C for 2 hours, and the thickness of the coating film was measured with a micrometer. The uniformity of the coating was imaged with a fluorescence in vivo imaging system (Neoscience, Suwon, Korea).
개질화된 클로린e6 또는 헤마토포르피린을 이용한 것은 용매 친화도를 높이고, PEG 또는 플루로닉과 같은 고분자와의 접합으로 분자량이 증가하면 스텐트 표면으로부터 유실률이 감소하기 때문이다. 개질화 방법은 DCC/NHS 촉매를 이용하여 아마이드 결합으로 고분자를 접합시키는 방법을 이용하였다.The use of modified chlorine e6 or hematoporphyrin increases solvent affinity, and the loss rate from the stent surface decreases as the molecular weight increases through conjugation with polymers such as PEG or pluronic. The reforming method used a method of conjugating polymers with amide bonds using a DCC/NHS catalyst.
실험예 1: 메틸렌블루 및 톨루이딘블루의 활성산소 형성능 확인Experimental Example 1: Confirmation of active oxygen forming ability of methylene blue and toluidine blue
1. 실험 목적1. Purpose of experiment
형광 색소로서 사용되는 메틸렌블루 또는 톨루이딘블루가 빛 조사에 따라 활성산소를 형성할 수 있는지 확인하기 위함이다.This is to check whether methylene blue or toluidine blue, which are used as fluorescent dyes, can form active oxygen upon light irradiation.
2. 실험 재료 및 방법2. Experimental materials and methods
상기 실시예 3 및 실시예 4에서 제조한 광응답성 스텐트의 빛 조사에 따른 활성산소 형성능을 확인하기 위해 일항 산소와 직접적으로 반응하는 형광 탐지 물질인 디메틸안트라센(9, 10-Dimethylanthracene, DMA)과 Singlet oxygen sensor green (SOSG)(InvitrogenTM)을 이용하였다. 디메틸안트라센을 DMSO가 0.8%(부피/부피%) 포함된 증류수에 분산시키고, SOSG는 메탄올이 0.1%(부피/부피%) 포함된 증류수에 분산시켜 활성산소 감지 용액을 제조하였다. 제조된 용액에 광응답성 스텐트를 넣고 670 ㎚ 파장의 빛을 20 ㎽/㎠의 세기로 20초간 반복 조사하여 4J 또는 8J까지 조사했을 때 형성되는 활성산소의 정도를 비교하였다.In order to confirm the ability of the photoresponsive stents prepared in Examples 3 and 4 to form active oxygen upon light irradiation, dimethylanthracene (9, 10-Dimethylanthracene, DMA), a fluorescent detection material that reacts directly with singlet oxygen, was used. Singlet oxygen sensor green (SOSG) (Invitrogen TM ) was used. An active oxygen sensing solution was prepared by dispersing dimethylanthracene in distilled water containing 0.8% (volume/volume%) of DMSO, and SOSG in distilled water containing 0.1% (volume/volume%) of methanol. A photoresponsive stent was placed in the prepared solution, and light with a wavelength of 670 nm was repeatedly irradiated at an intensity of 20 mW/cm2 for 20 seconds to compare the degree of active oxygen formed when irradiated up to 4J or 8J.
3. 결과3. Results
메틸렌블루 및 톨루이딘블루 모두 빛의 세기가 강해짐에 따라 발생한 활성산소를 탐지할 수 있는 SOSG의 형광 강도가 증가하는 것을 확인하였다. 반면, DMA와 반응시킨 경우 활성산소가 포집됨에 따라 형광을 잃게 되기 때문에 형광강도가 감소하는 것을 알 수 있었다 (도 10).It was confirmed that the fluorescence intensity of SOSG, which can detect generated oxygen radicals, increased as the intensity of light for both methylene blue and toluidine blue increased. On the other hand, when reacted with DMA, fluorescence intensity was found to decrease because fluorescence was lost as active oxygen was captured (FIG. 10).
4. 결과에 따른 결론4. Conclusion based on results
빛을 조사함에 따라 SOSG의 형광 강도는 증가하고, DMA의 형광 강도는 감소하였으므로 활성산소가 많이 형성되는 것을 확인할 수 있었다. 또한, DMA의 형광 강도를 통해 수상 및 유기용매 상에서 메틸렌블루와 톨루이딘블루의 활성산소 형성능이 거의 유사하고, 메틸렌블루 또는 톨루이딘블루의 농도가 높아짐에 따라 활성산소 형성능이 증진되는 것을 알 수 있었다.As light was irradiated, the fluorescence intensity of SOSG increased and that of DMA decreased, confirming that a large amount of active oxygen was formed. In addition, through the fluorescence intensity of DMA, it was found that the active oxygen forming ability of methylene blue and toluidine blue in the aqueous phase and the organic solvent phase was almost similar, and that the active oxygen forming ability increased as the concentration of methylene blue or toluidine blue increased.
실험예 2: 메틸렌블루 및 톨루이딘블루의 세포 광독성 확인Experimental Example 2: Confirmation of cell phototoxicity of methylene blue and toluidine blue
1. 실험 목적1. Purpose of experiment
형광 색소로 사용되는 메틸렌블루 또는 톨루이딘블루의 세포독성을 확인하고 빛 조사에 의한 세포독성이 있는지 확인하기 위함이다.This is to check the cytotoxicity of methylene blue or toluidine blue, which are used as fluorescent dyes, and to determine whether there is cytotoxicity due to light irradiation.
2. 실험 재료 및 방법2. Experimental materials and methods
메틸렌블루 또는 톨루이딘블루의 세포독성을 확인하기 위해 마우스 섬유아세포(L929)와 사람 위 세포(AGS) 세포를 48 웰(well)에 2x104 cells/well의 농도로 각 웰에 0.2 ㎖씩 분주하고 37℃, 5% CO2 조건에서 24시간 동안 배양하였다. 각각의 세포에 다양한 농도의 메틸렌블루 또는 톨루이딘블루를 처리하여 4시간 동안 배양하였다. 이후, 배양액을 교환하면서 빛을 1J, 2J, 5J 또는 10J로 조사하고 24시간 동안 추가로 배양하였다. 세포 생존율은 MTT 시험법으로 확인하였다.To check the cytotoxicity of methylene blue or toluidine blue, mouse fibroblasts (L929) and human gastric cells (AGS) cells were dispensed into 48 wells at a concentration of 2x10 cells/well, 0.2 ml each well, and 37 Cultivated for 24 hours at ℃, 5% CO 2 conditions. Each cell was treated with various concentrations of methylene blue or toluidine blue and cultured for 4 hours. Afterwards, while exchanging the culture medium, light was irradiated at 1J, 2J, 5J, or 10J and cultured for an additional 24 hours. Cell viability was confirmed using the MTT test.
3. 결과3. Results
광원을 조사하지 않으면 L929, AGS 세포에서 모두 5 ㎍/㎖ 이상의 농도에서 세포생존율 50% 이하로 나타났다. 광원을 조사한 경우 조사하지 않은 경우에 비해 생존율이 더 많이 감소하는 것을 확인하였다. 메틸렌블루의 경우 빛의 세기가 강해질수록 더 낮은 세포 생존율을 보였다 (도 11).If the light source was not irradiated, cell viability was less than 50% in both L929 and AGS cells at concentrations above 5 μg/ml. It was confirmed that the survival rate decreased more when the light source was irradiated compared to when the light source was not irradiated. In the case of methylene blue, the cell survival rate was lower as the light intensity increased (Figure 11).
4. 결과에 따른 결론4. Conclusion based on results
형광 색소인 메틸렌블루와 톨루이딘블루는 광원의 유무에 따라 세포독성 여부에 차이가 있으며, 이는 광응답성 스텐트를 제조하기 위한 후보물질로서의 충분한 특성을 지닌다.The fluorescent dyes methylene blue and toluidine blue have different cytotoxicity depending on the presence or absence of a light source, and have sufficient properties as candidate materials for manufacturing light-responsive stents.
실험예 3: 메틸렌블루 및 톨루이딘블루가 코팅된 광응답성 스텐트 관찰Experimental Example 3: Observation of light-responsive stent coated with methylene blue and toluidine blue
1. 실험 목적1. Purpose of experiment
상기 실시예 3 및 실시예 4에서 제조한 광응답성 스텐트의 메틸렌블루 및 톨루이딘블루의 스텐트 표면 코팅 정도와 코팅의 균일성을 판단하기 위해 광학 이미지, 형광 이미지, 및 전자현미경을 통한 이미지를 확인하기 위한 목적이 있다.To determine the extent of stent surface coating of methylene blue and toluidine blue of the light-responsive stents prepared in Examples 3 and 4 and the uniformity of the coating, check the images through optical images, fluorescence images, and electron microscopy. There is a purpose for it.
2. 실험 재료 및 방법2. Experimental materials and methods
상기 실시예 3 및 실시예 4에서 제조한 광응답성 스텐트에 코팅된 정도를 판단하기 위하여 형광 색소 자체의 형광 성질을 이용하여 형광 이미지 시스템 (Fluorescence in vivo imaging system, Suwon, Korea)으로 형광 이미지를 촬영하였다. 이미지의 형광강도는 NEOimage 소프트웨어로 정량하였다. 스텐트 표면은 전자현미경으로 3 KV의 조건에서 확인하였다.In order to determine the degree of coating on the light-responsive stents prepared in Examples 3 and 4, fluorescence images were taken using a fluorescence in vivo imaging system (Fluorescence in vivo imaging system, Suwon, Korea) using the fluorescence properties of the fluorescent dye itself. Filmed. The fluorescence intensity of the image was quantified using NEOimage software. The stent surface was confirmed under 3 KV conditions using an electron microscope.
3. 결과 확인3. Check the results
실시예 4에서 제조한 광응답성 스텐트의 광학 사진과 형광 사진을 확인한 결과, 색소가 균일하게 코팅된 것을 확인할 수 있었다 (도 12). 또한, 실시예 3에서 제조한 광응답성 스텐트는 표면이 매우 거칠었으며, 2주 간의 용출 후에는 거친 정도가 더욱 고조되었다. 반면 실시예 4에서 제조한 광응답성 스텐트는 실시예 3에서 제조한 광응답성 스텐트와 비교하여 매끄러운 표면을 갖는 것을 알 수 있었다. 이는 2주 용출 후에도 매끄럽게 유지되었다 (도 13).As a result of checking the optical and fluorescence photographs of the light-responsive stent manufactured in Example 4, it was confirmed that the dye was uniformly coated (FIG. 12). In addition, the light-responsive stent manufactured in Example 3 had a very rough surface, and the roughness further increased after two weeks of dissolution. On the other hand, the light-responsive stent manufactured in Example 4 was found to have a smooth surface compared to the light-responsive stent manufactured in Example 3. It remained smooth even after 2 weeks of dissolution (Figure 13).
4. 결과에 따른 결론4. Conclusion based on results
상기 실시예 3에서 제조한 광응답성 스텐트는 용매 혼화도가 개선되지 않아 용매에 완전히 녹지 못한 채 코팅되어 입자 형태가 표면에 달라붙은 것을 확인할 수 있었다. 이는 이후 용출 실험에도 영향을 미친 것으로 나타났으며, 2주간의 용출 후에는 표면이 더욱 거칠어졌다. 반면, 실시예 4에서 제조한 광응답성 스텐트는 혼화도가 개선되어 균일한 코팅이 이루어졌으며, 이에 따라 표면에 입자가 관찰되지 않았다. 따라서, 코팅물질에 있어 최적의 용매 혼화도 개선이 필요한 것으로 판단된다.It was confirmed that the light-responsive stent prepared in Example 3 was coated without being completely dissolved in the solvent due to the solvent miscibility not being improved, and the particle shape was adhered to the surface. This appeared to have an effect on subsequent dissolution experiments, and the surface became rougher after two weeks of dissolution. On the other hand, the light-responsive stent prepared in Example 4 had improved miscibility and uniform coating, and thus no particles were observed on the surface. Therefore, it is deemed necessary to improve optimal solvent miscibility in coating materials.
실험예 4: 스텐트에 코팅된 메틸렌블루 및 톨루이딘블루의 단위면적당 농도 산출Experimental Example 4: Calculation of concentration per unit area of methylene blue and toluidine blue coated on stent
1. 실험 목적1. Purpose of experiment
상기 실시예 3 및 실시예 4에서 제조한 광응답성 스텐트에 코팅된 형광 색소 양을 산출하기 위함이다.This is to calculate the amount of fluorescent dye coated on the photoresponsive stent prepared in Example 3 and Example 4.
2. 실험 재료 및 방법2. Experimental materials and methods
상기 실시예 3 및 실시예 4에서 제조한 광응답성 스텐트의 박막을 용해하기 위해 실리콘과 혼화된 용액을 이용한 경우 자일렌:메탄올 (7:3) 용액 5 ㎖, 폴리우레탄과 혼화된 용액을 이용한 경우 테트라하이드로푸란 : 메탄올 (7:3) 용액을 5 ㎖을 이용하였다. 제조된 용출 용액에 스텐트를 넣고 250 rpm, 25℃에서 48시간 동안 회전 교반기로 교반하였다. 용해된 메틸렌블루 및 톨루이딘블루의 양은 UV 분광 광도계로 정량하고, 스텐트의 단위면적을 측정해 단위면적 대비 메틸렌블루 및 톨루이딘블루의 양을 산출하였다.When using a solution mixed with silicon to dissolve the thin film of the light-responsive stent prepared in Example 3 and Example 4, 5 ml of xylene:methanol (7:3) solution, using a solution mixed with polyurethane In this case, 5 ml of tetrahydrofuran:methanol (7:3) solution was used. The stent was added to the prepared elution solution and stirred with a rotary stirrer at 250 rpm and 25°C for 48 hours. The amount of dissolved methylene blue and toluidine blue was quantified using a UV spectrophotometer, and the unit area of the stent was measured to calculate the amount of methylene blue and toluidine blue per unit area.
3. 결과 확인3. Check the results
상기 실시예 3에서 제조한 광응답성 스텐트에 코팅된 메틸렌블루의 양은 실리콘을 이용한 경우 39.3 ㎍, 폴리우레탄을 이용한 경우 123.2 ㎍이었다. 코팅된 톨루이딘블루의 양은 실리콘을 이용한 경우 53.3 ㎍, 폴리우레탄을 이용한 경우 141.8 ㎍이었다. 상기 실시예 4에서 제조한 광응답성 스텐트에 코팅된 메틸렌블루의 양은 실리콘을 이용한 경우 225.4 ㎍, 폴리우레탄을 이용한 경우 538 ㎍이었다. 코팅된 톨루이딘블루의 양은 실리콘을 이용한 경우 219.8 ㎍, 폴리우레탄을 이용한 경우 424.7 ㎍이었다 (도 14).The amount of methylene blue coated on the light-responsive stent prepared in Example 3 was 39.3 μg when silicone was used and 123.2 μg when polyurethane was used. The amount of coated toluidine blue was 53.3 μg when silicone was used and 141.8 μg when polyurethane was used. The amount of methylene blue coated on the light-responsive stent prepared in Example 4 was 225.4 μg when silicone was used and 538 μg when polyurethane was used. The amount of coated toluidine blue was 219.8 μg when silicone was used and 424.7 μg when polyurethane was used (FIG. 14).
4. 결과에 따른 결론4. Conclusion based on results
메틸렌블루 또는 톨루이딘블루를 실리콘 또는 폴리우레탄과 혼화하여 딥핑법으로 코팅하였을 때, 용매 혼화도가 개선되지 않은 용액에서 코팅할 때와 비교하여 현저히 많은 양의 형광 색소가 코팅된다.When methylene blue or toluidine blue is mixed with silicone or polyurethane and coated by the dipping method, a significantly larger amount of fluorescent dye is coated compared to when coated in a solution in which solvent miscibility is not improved.
실험예 5: 메틸렌블루 및 톨루이딘블루가 코팅된 광응답성 스텐트의 활성산소 형성능 비교Experimental Example 5: Comparison of active oxygen formation ability of light-responsive stents coated with methylene blue and toluidine blue
1. 실험 목적1. Purpose of experiment
상기 실시예 3 및 실시예 4에서 제조한 광응답성 스텐트의 빛 조사 세기에 따른 혈성산소 형성능을 확인하고, 반복 실험을 진행하였을 때 용출된 형광 색소에 의한 형성능의 감소 여부를 비교하기 위함이다.The purpose was to confirm the blood oxygen forming ability of the photoresponsive stents prepared in Examples 3 and 4 according to the light irradiation intensity and to compare whether the forming ability was reduced due to the eluted fluorescent dye when repeated experiments were performed.
2. 실험 재료 및 방법2. Experimental materials and methods
상기 실시예 3 및 실시예 4에서 제조한 스텐트 조각을 가로X세로 (1 ㎝ X 1 ㎝ = 1 ㎠)으로 제작하여 실험을 진행하였다. 스텐트 조각을 RF 큐벳에 위치하고, 활성산소를 탐지할 수 있는 Singlet oxygen sensor green(SOSG, Thermofisher science)가 용해된 시험용액을 RF 큐벳에 2 ㎖씩 넣어주었다. SOSG 용액은 증류수에 최종 10 μM의 농도가 되도록 증류수를 이용하여 제작하였다. 671 ㎚의 빛을 20 ㎽/㎠의 세기로 20초씩 반복 조사하여 총 10 J (W·s/㎠) 조사했으며, 20초 조사할 때마다 Radio frequency 분광분석기를 이용하여 Ex/Em = 504/525 ㎚의 파장대에서 형광강도를 검출하였다.The stent pieces prepared in Example 3 and Example 4 were fabricated in a horizontal A piece of the stent was placed in an RF cuvette, and 2 ml of a test solution in which Singlet oxygen sensor green (SOSG, Thermofisher science), which can detect active oxygen, was dissolved was added to the RF cuvette. The SOSG solution was prepared using distilled water to a final concentration of 10 μM. Light of 671 nm was irradiated repeatedly for 20 seconds at an intensity of 20 mW/cm2 for a total of 10 J (W·s/cm2), and Ex/Em = 504/525 using a radio frequency spectrometer for each 20 second irradiation. Fluorescence intensity was detected in the wavelength range of ㎚.
3. 결과 확인3. Check the results
상기 실시예 3에서 제작한 용매 혼화도가 개선되지 않은 메틸렌블루 또는 톨루이딘블루가 코팅된 스텐트는 코팅 용매와 무관하게 첫 번째 측정 결과 대비 두 번째 측정 결과에서 SOSG 형광강도가 현저히 감소한 것을 확인할 수 있었다 (도 15 및 도 16). It was confirmed that the SOSG fluorescence intensity of the stent coated with methylene blue or toluidine blue, which did not improve solvent miscibility manufactured in Example 3, was significantly reduced in the second measurement result compared to the first measurement result, regardless of the coating solvent ( 15 and 16).
반면, 상기 실시예 4에서 제조한 용매 혼화도가 개선된 광응답성 스텐트는 코팅 용매로 자일렌을 이용하였을 때 첫 번째 측정 결과와 두 번째 측정 결과에서 SOSG 형광강도가 거의 차이가 없었다 (도 15). 코팅 용매로 THF를 이용하면 첫 번째 측정 결과 대비 두 번째 측정 결과에서 SOSG 형광강도가 다소 감소하였다 (도 16).On the other hand, when the photoresponsive stent with improved solvent miscibility prepared in Example 4 used xylene as a coating solvent, there was almost no difference in SOSG fluorescence intensity between the first and second measurement results (FIG. 15 ). When THF was used as a coating solvent, the SOSG fluorescence intensity slightly decreased in the second measurement result compared to the first measurement result (FIG. 16).
또한, 실시예 4에서 제조한 용매 혼화도가 개선된 광응답성 스텐트에 빛을 반복 조사했을 때, 활성산소를 형성할 수 있는지 24시간마다 확인한 결과, 활성 산소가 반복적으로 형성되는 것을 알 수 있었다 (도 17).In addition, when light was repeatedly irradiated to the photoresponsive stent with improved solvent miscibility prepared in Example 4, it was checked every 24 hours whether active oxygen could be formed, and it was found that active oxygen was formed repeatedly. (Figure 17).
4. 결과에 따른 결론4. Conclusion based on results
형광 색소의 용해도가 개선되기 전에는 형광 색소가 초기에 과량 용출되어 활성산소 형성능 또한 초기에 높은 것으로 나타났다. 그러나 두 번째 측정값과는 활성산소 형성능이 확연히 차이나 스텐트의 반복 사용에 적합하지 않다. 하지만, 용해도가 개선되면 무작위적인 용출이 발생하지 않기 때문에 첫 번째 측정값과 두 번째 측정값이 유사하게 측정되어 반복 사용에 적합함을 알 수 있다.Before the solubility of the fluorescent dye was improved, the fluorescent dye was initially excessively eluted and the active oxygen forming ability was also initially high. However, the oxygen forming ability is clearly different from the second measurement value, so it is not suitable for repeated use of the stent. However, when solubility is improved, random dissolution does not occur, so the first and second measurements are similar, indicating that it is suitable for repeated use.
실험예 6: 광응답성 스텐트에 코팅된 메틸렌블루 및 톨루이딘블루의 유실률 비교Experimental Example 6: Comparison of loss rates of methylene blue and toluidine blue coated on light-responsive stents
1. 실험 목적1. Purpose of experiment
상기 실시예 3 및 실시예 4에서 제조한 광응답성 스텐트에 코팅된 메틸렌블루 및 톨루이딘블루의 시간에 따른 유실 여부를 확인하기 위함이다.This is to check whether the methylene blue and toluidine blue coated on the light-responsive stents prepared in Example 3 and Example 4 are lost over time.
2. 실험 재료 및 방법2. Experimental materials and methods
상기 실시예 3 및 실시예 4에서 제조한 광응답성 스텐트 표면에 코팅된 친수성 형광 색소 유실 정도를 체내 환경에서 확인하기 위해 스텐트를 인산완충액 (pH 7.0, 37℃)에 담그고, 50 rpm으로 교반하였다. 시간의 흐름에 따라 형광사진 촬영 및 용출된 형광 색소를 UV 정량과 함께 진행하였다.To confirm the degree of loss of the hydrophilic fluorescent dye coated on the surface of the light-responsive stent prepared in Examples 3 and 4 in the in vivo environment, the stent was immersed in phosphate buffer solution (pH 7.0, 37°C) and stirred at 50 rpm. . Over time, fluorescence photography and UV quantification of the eluted fluorescent dye were performed.
3. 결과 확인3. Check the results
상기 실시예 3 및 실시예 4에서 제조한 광응답성 스텐트의 유실률을 2주 동안 비교하였다. 실리콘과 메틸렌블루를 혼화하여 코팅한 경우 가용화 전에는 총 86.44% (방출량 33.97 ㎍, 초기 코팅량 39.3 ㎍), 가용화 후에는 총 8.59% (방출량 19.36 ㎍, 초기 코팅량 225.4 ㎍)이 형광 색소가 용출되었다. 실리콘과 톨루이딘블루를 혼화하여 코팅한 경우 가용화 전에는 총 57.33% (방출량 30.56 ㎍, 초기 코팅량 53.3 ㎍), 가용화 후에는 총 4.36% (방출량 9.58 ㎍, 초기 코팅량 219.8 ㎍)의 색소가 용출되었다 (도 18 및 표 2).The loss rates of the light-responsive stents manufactured in Example 3 and Example 4 were compared for 2 weeks. When silicone and methylene blue were mixed and coated, a total of 86.44% (released amount: 33.97 μg, initial coating amount: 39.3 μg) was eluted before solubilization, and a total of 8.59% (released amount: 19.36 μg, initial coating amount: 225.4 μg) was eluted after solubilization. . When silicone and toluidine blue were mixed and coated, a total of 57.33% (released amount: 30.56 μg, initial coating amount: 53.3 μg) was eluted before solubilization, and a total of 4.36% (released amount: 9.58 μg, initial coating amount: 219.8 μg) was eluted after solubilization ( Figure 18 and Table 2).
폴리우레탄과 메틸렌블루를 혼화하여 코팅한 경우 가용화 전에는 총 77.63% (방출량 95.64 ㎍, 초기 코팅량 123.2 ㎍), 가용화 개선 후에는 총 85.65% (방출량 460.80 ㎍, 초기 코팅량 538 ㎍) 용출되었다. 폴리우레탄과 톨루이딘블루를 혼화하여 코팅한 경우 가용화 전에는 총 83.66% (방출량 118.63 ㎍, 초기 코팅량 141.8 ㎍), 가용화 개선 후에는 총 97.68% (방출량 414.85 ㎍, 초기 코팅량 427.85 ㎍) 용출되었다 (도 19 및 표 3).When polyurethane and methylene blue were mixed and coated, a total of 77.63% (released amount: 95.64 μg, initial coating amount: 123.2 μg) was eluted before solubilization, and after solubilization was improved, a total of 85.65% (released amount: 460.80 μg, initial coating amount: 538 μg) was eluted. When polyurethane and toluidine blue were mixed and coated, a total of 83.66% (released amount: 118.63 μg, initial coating amount: 141.8 μg) was eluted before solubilization, and after solubilization, a total of 97.68% (released amount: 414.85 μg, initial coating amount: 427.85 μg) was eluted (Figure 19 and Table 3).
4. 결과에 따른 결론4. Conclusion based on results
실리콘과 메틸렌블루를 혼화하여 코팅한 경우 가용화를 개선함에 따라 2주 후의 유실율이 약 10배 정도 감소하였다. 실리콘과 톨루이딘블루를 혼화하여 코팅한 경우 가용화도를 개선함에 따라 2주 후의 유실율이 약 13배 정도 감소했다. 폴리우레탄과 메틸렌블루를 혼화하여 코팅한 경우 가용화를 개선함에 따라 2주 후의 유실율이 약 10배 정도 감소하였다. 폴리우레탄의 경우 가용화도 개선에 따른 유실율의 변화는 눈에 띄게 관찰되지 않았다. 본 발명의 의료기기 코팅용 조성물을 사용하면 색소의 유지 기간이 월등히 증대하므로 종래의 광역학 치료 효과를 극대화시킬 수 있다.When silicone and methylene blue were mixed and coated, the loss rate after 2 weeks decreased by about 10 times as solubilization was improved. When silicone and toluidine blue were mixed and coated, the loss rate after 2 weeks decreased by about 13 times as solubilization was improved. When polyurethane and methylene blue were mixed and coated, the loss rate after 2 weeks decreased by about 10 times as solubilization was improved. In the case of polyurethane, no noticeable change in loss rate was observed due to improvement in solubilization. When the composition for coating medical devices of the present invention is used, the retention period of the pigment is significantly increased, thereby maximizing the effect of conventional photodynamic treatment.
실험예 7: 메틸렌블루 및 톨루이딘블루가 코팅된 광응답성 스텐트의 빛에 의한 세포 사멸률 확인Experimental Example 7: Confirmation of cell death rate by light of photoresponsive stent coated with methylene blue and toluidine blue
1. 실험 목적1. Purpose of experiment
상기 실시예 3 및 실시예 4에서 제조한 광응답성 스텐트의 빛에 의한 세포 사멸능을 확인하기 위함이다.This is to confirm the cell killing ability by light of the photoresponsive stent manufactured in Example 3 and Example 4.
2. 실험 재료 및 방법2. Experimental materials and methods
상기 실시예 4에서 제조한 광응답성 스텐트의 빛에 의한 세포사멸을 육안으로 확인하기 위해 트립판블루 염색법(Trypan Blue Staining)을 이용하였다. 사람 췌장암세포 (PANC1)을 12wells 세포 배양 플레이트에 5 X 105 cells/well로 분주한다. 24시간 후, 플레이트에 부착된 세포 위에 광응답성 스텐트 조각(7 ㎜ X 7 ㎜, 가로 X 세로)을 올려두고, 670 ㎚의 빛을 1J (50 mW/㎠, 20초) 조사하였다. 30분 후, 4% 트립판블루 용액을 넣어 15분 동안 염색시키고 DPBS를 통해 잔여 트립판블루를 세척한 뒤 현미경을 통해 관찰하였다.Trypan blue staining was used to visually confirm cell death caused by light in the light-responsive stent prepared in Example 4. Human pancreatic cancer cells (PANC1) were distributed at 5 After 24 hours, a light-responsive stent piece (7 mm After 30 minutes, 4% trypan blue solution was added and stained for 15 minutes. The remaining trypan blue was washed with DPBS and observed through a microscope.
3. 결과 확인3. Check the results
상기 실시예 4에서 제조한 스텐트 막을 단일층으로 형성된 세포 위에 얹어 빛을 조사했을 때 빛의 세기가 높아질수록, 코팅용액의 농도가 높아질수록 트리판블루에 의해 염색된 보라색 세포들이 많이 관찰되어 세포가 사멸된 것을 알 수 있었다 (도 20).When the stent membrane prepared in Example 4 was placed on the cells formed as a single layer and irradiated with light, as the intensity of light increased and the concentration of the coating solution increased, more purple cells stained with trypan blue were observed, and the cells It was found that it had died (Figure 20).
4. 결과에 따른 결론4. Conclusion based on results
스텐트 막에 코팅된 메틸렌블루는 단순 빛 조사만으로 스텐트 조각과 직접적으로 맞닿은 세포를 사멸할 수 있다. 빛의 세기가 5 J인 경우 0.05 ㎎/㎖로 코팅된 스텐트막을 제외하고 모두 효과를 보였으며, 빛의 세기가 강해질수록 코팅용액의 농도가 높아질수록 세포가 많이 사멸한 것을 확인할 수 있었다.Methylene blue coated on the stent membrane can kill cells directly in contact with the stent piece with simple light irradiation. When the light intensity was 5 J, all but the stent membrane coated at 0.05 mg/ml showed an effect, and it was confirmed that as the light intensity became stronger and the concentration of the coating solution increased, more cells died.
본 발명에서 개발된 광응답성 스텐트는 빛을 조사함에 따라 활성산소를 형성하므로 스텐트 접촉 부위에서의 세포사멸을 기대할 수 있고, 활성산소는 매우 근접한 거리에서 일시적으로 영향을 미칠 수 있기 때문에, 국소부위의 세포사멸을 기대할 수 있다.The photoresponsive stent developed in the present invention forms active oxygen upon irradiation of light, so cell death can be expected at the stent contact site, and since active oxygen can temporarily affect the local area at a very close distance, Cell death can be expected.
실험예 8: 친수성으로 개질화된 클로린e6가 코팅된 광응답성 스텐트 관찰Experimental Example 8: Observation of a photoresponsive stent coated with hydrophilically modified chlorine e6
1. 실험 목적1. Purpose of experiment
상기 실시예 5에서 제조한 광응답성 스텐트의 친수성 클로린e6 및 헤마토포르피린의 스텐트 표면 코팅 정도와 코팅의 균일성을 판단하기 위해 광학 이미지, 형광 이미지를 확인하기 위함이다.This is to check optical images and fluorescence images to determine the degree of coating of the stent surface with hydrophilic chlorine e6 and hematoporphyrin of the light-responsive stent prepared in Example 5 and the uniformity of the coating.
2. 실험 재료 및 방법2. Experimental materials and methods
상기 실시예 5에서 제조한 광응답성 스텐트에 코팅된 정도를 판단하기 위하여 클로린e6 및 헤마토포르피린의 형광 성질을 이용하여 형광 이미지 시스템 (Fluorescence in vivo imaging system, Suwon, Korea)으로 촬영하였다.In order to determine the degree of coating on the light-responsive stent prepared in Example 5, images were taken using a fluorescence in vivo imaging system (Fluorescence in vivo imaging system, Suwon, Korea) using the fluorescence properties of chlorine e6 and hematoporphyrin.
3. 결과에 따른 결론3. Conclusion based on results
상기 실시예 5에서 제조한 광응답성 스텐트는 실리콘만 코팅된 대조군(CON)은 형광이 검출되지 않았지만, 광응답제가 코팅된 경우 형광 tlsgh가 검출되었다. 친수성으로 개질화되지 않은 단일 클로린e6와 단일 헤마토포르피린보다 개질화되어 분자량이 커진 클로린e6 및 헤마토포르피린이 더 강한 형광강도로 검출되었다. 클로린e6 및 헤마토포르피린은 화학적 개질화가 진행되었음에도 불구하고 스텐트 표면에 균일하게 잘 코팅되는 것을 확인할 수 있었다 (도 21).In the light-responsive stent prepared in Example 5, no fluorescence was detected in the control group (CON) coated only with silicon, but fluorescence tlsgh was detected when the stent was coated with a photoresponsive agent. Chlorine e6 and hematoporphyrin, which were modified to have a larger molecular weight, were detected with stronger fluorescence intensity than single chlorine e6 and single hematoporphyrin that were not hydrophilically modified. It was confirmed that chlorine e6 and hematoporphyrin were uniformly coated on the stent surface despite chemical modification (FIG. 21).
실험예 9: 친수성으로 개질화된 클로린e6가 코팅된 광응답성 스텐트의 활성산소 형성능 확인Experimental Example 9: Confirmation of active oxygen forming ability of photoresponsive stent coated with hydrophilically modified chlorine e6
1. 실험 목적1. Purpose of experiment
상기 실시예 5에서 제조한 광응답성 스텐트의 빛 조사 세기에 따른 혈성산소 형성능을 확인하기 위함이다.This is to confirm the blood oxygen forming ability of the light-responsive stent manufactured in Example 5 according to the light irradiation intensity.
2. 실험 재료 및 방법2. Experimental materials and methods
상기 실시예 5에서 제조한 스텐트 조각을 가로X세로 (1 ㎝ X 1 ㎝ = 1 ㎠)으로 제작하여 실험을 진행하였다. 스텐트 조각을 RF 큐벳에 위치하고, 활성산소를 탐지할 수 있는 Singlet oxygen sensor green(SOSG, Thermofisher science)가 용해된 시험용액을 RF 큐벳에 2 ㎖식 넣어주었다. SOSG 용액은 증류수에 최종 10μM의 농도가 되도록 제작하였다. 671 ㎚의 빛을 20 mW/㎠의 세기로 20초씩 반복 조사하여 총 8J(W·s/㎠) 조사했으며, 20초 조사할 때마다 RF 분광분석기를 이용하여 Ex/Em = 504/525 ㎚의 파장대에서 형광강도를 검출하였다.The stent piece prepared in Example 5 was fabricated in a horizontal The stent piece was placed in the RF cuvette, and 2 ml of test solution containing Singlet oxygen sensor green (SOSG, Thermofisher science), which can detect active oxygen, was dissolved in the RF cuvette. The SOSG solution was prepared in distilled water to a final concentration of 10 μM. Light of 671 ㎚ was irradiated repeatedly for 20 seconds at an intensity of 20 mW/㎠ for a total of 8J (W·s/㎠), and each 20 seconds of irradiation was used to measure Ex/Em = 504/525 ㎚ using an RF spectrometer. Fluorescence intensity was detected in the wavelength range.
3. 결과 확인 및 결론3. Confirmation of results and conclusion
상기 실시예 5에서 제조한 메톡시폴리에틸렌글리콜5k-클로린e6, 플루로닉F127-클로린e6, 및 플루로닉F127-헤마토포르피린이 코팅된 스텐트 조각을 이용하여 레이저 조사에 따른 활성산소 형성능을 확인했다. 화학반응을 통한 개질화가 진행되었음에도 불구하고 광응답제의 활성산소 형성능이 유지되는 것을 확인할 수 있었다 (도 22).The ability to form active oxygen upon laser irradiation was confirmed using stent pieces coated with methoxypolyethylene glycol 5k-chlorine e6, pluronic F127-chlorine e6, and pluronic F127-hematoporphyrin prepared in Example 5. did. It was confirmed that the photoresponsive agent's ability to form active oxygen was maintained despite reforming through chemical reaction (FIG. 22).
실험예 10: 광응답성 스텐트에 코팅된 친수성 클로린e6 및 헤마토포르피린의 유실률 비교Experimental Example 10: Comparison of loss rates of hydrophilic chlorine e6 and hematoporphyrin coated on light-responsive stents
1. 실험 목적1. Purpose of experiment
상기 실시예 5에서 제조한 광응답성 스텐트에 코팅된 친수성 클로린e6 및 헤마토포르피린의 시간에 따른 유실 여부를 확인하기 위함이다.This is to check whether the hydrophilic chlorine e6 and hematoporphyrin coated on the light-responsive stent prepared in Example 5 are lost over time.
2. 실험 재료 및 방법2. Experimental materials and methods
상기 실시예 5에서 제조한 광응답성 스텐트 표면에 코팅된 친수성 클로린e6 및 헤마토포르피린의 유실을 체내 환경에서 확인하고자 인산완충액 (pH 7.0, 37℃)에서 실험하였다. 대조군으로 개질되지 않은 단일 클로린e6와 단일 헤마토포르피린은 소수성 약물임을 감안하여 계면활성제가 첨가된 인산완충액 (0.1% Tween20, pH 7.0, 37℃)에서 실험하였다. 실리콘 필름이 담긴 인산완충액을 50 rpm으로 교반하여, 시간의 흐름에 따라 용출된 물질을 UV 정량 분석하였다.To confirm the loss of hydrophilic chlorine e6 and hematoporphyrin coated on the surface of the light-responsive stent prepared in Example 5 in the in vivo environment, an experiment was conducted in phosphate buffer solution (pH 7.0, 37°C). As a control group, unmodified single chlorine e6 and single hematoporphyrin were tested in phosphate buffer solution (0.1% Tween20, pH 7.0, 37°C) with added surfactant, considering that they are hydrophobic drugs. The phosphate buffer solution containing the silicone film was stirred at 50 rpm, and the eluted material was quantitatively analyzed by UV over time.
3. 결과 확인 및 결론3. Confirmation of results and conclusion
상기 실시예 5에서 제조한 광응답성 스텐트의 유실률을 5일간 비교하였다. 단일 클로린e6의 경우 실리콘 필름을 1.00 ㎎/㎖ 농도의 용액으로 제작한 경우 23.53%, 개질화한 경우 분자량의 증가로 6.01% 유실된 것을 확인할 수 있었다. 단일 헤마토포르피린의 경우 실리콘 필름을 1.00 ㎎/㎖ 농도로 용액을 제작한 경우 14.54%, 개질화한 경우 분자량의 증가로 2.43% 유실된 것을 확인할 수 있었다 (도 23).The loss rate of the light-responsive stent manufactured in Example 5 was compared for 5 days. In the case of single chlorine e6, it was confirmed that 23.53% was lost when the silicone film was produced with a solution with a concentration of 1.00 mg/ml, and when it was modified, 6.01% was lost due to an increase in molecular weight. In the case of a single hematoporphyrin, it was confirmed that 14.54% was lost when the silicone film was prepared as a solution at a concentration of 1.00 mg/ml, and when it was modified, 2.43% was lost due to an increase in molecular weight (FIG. 23).
따라서, 클로린e6와 헤마토포르피린은 화학적 접합에 의해 개질화되면서 분자량이 증가하여 스텐트 표면에서의 유실율을 감소시킬 수 있는 효과를 기대할 수 있다.Therefore, as chlorine e6 and hematoporphyrin are modified by chemical conjugation, the molecular weight increases, which can be expected to reduce the loss rate from the stent surface.
Claims (12)
상기 의료용 색소는 메틸렌블루, 톨루이딘 블루, 인도시아닌그린, 프탈로시아닌, 클로린 e6 및 헤마토포르피린으로 이루어진 군에서 선택되고,
상기 의료기기 코팅용 고분자는 실리콘 혼화물 또는 우레탄인, 의료기기 코팅용 조성물.A composition for coating medical devices consisting of a medical pigment, a miscible solvent in which the medical pigment is dispersed, a surfactant, a coating solvent, and a polymer for coating medical devices,
The medical dye is selected from the group consisting of methylene blue, toluidine blue, indocyanine green, phthalocyanine, chlorine e6, and hematoporphyrin,
A composition for coating medical devices, wherein the polymer for coating medical devices is a silicone mixture or urethane.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/KR2021/013104 WO2022065942A1 (en) | 2020-09-25 | 2021-09-27 | Composition for coating medical device |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200124438 | 2020-09-25 | ||
| KR20200124438 | 2020-09-25 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20220041714A KR20220041714A (en) | 2022-04-01 |
| KR102621315B1 true KR102621315B1 (en) | 2024-01-08 |
Family
ID=81183297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020210088341A KR102621315B1 (en) | 2020-09-25 | 2021-07-06 | Composition for coating medical devices |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102621315B1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014028287A (en) * | 2007-10-03 | 2014-02-13 | General Hospital Corp | Photochemical tissue bonding |
| US20150374516A1 (en) * | 2014-06-27 | 2015-12-31 | Boston Scientific Scimed, Inc. | Compositions, devices, kits and methods for attaching stent-containing medical devices to tissue |
| KR101874265B1 (en) * | 2017-11-23 | 2018-07-03 | 주식회사 비앤디네트웍스 | Pharmaceutical Composition containing Photosensitizer for Periodontitis |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9700396D0 (en) * | 1997-01-10 | 1997-02-26 | Photocure As | Photochemotherapeutic compositions |
| KR101200210B1 (en) * | 2009-11-10 | 2012-11-09 | 가톨릭대학교 산학협력단 | Photosensitizer coated stent for medical use and manufacturing method thereof |
| KR101217615B1 (en) * | 2010-08-11 | 2013-01-02 | 연세대학교 산학협력단 | A photo-functional self-cleaned stent and method for preparing the same |
| KR101722036B1 (en) | 2013-12-26 | 2017-03-31 | 주식회사 삼양바이오팜 | A drug coating agent for a biodegradable stent with controlled drug release and a method for preparing the same, and a biodegradable stent coated with the agent and a method for preparing the same |
-
2021
- 2021-07-06 KR KR1020210088341A patent/KR102621315B1/en active IP Right Grant
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014028287A (en) * | 2007-10-03 | 2014-02-13 | General Hospital Corp | Photochemical tissue bonding |
| US20150374516A1 (en) * | 2014-06-27 | 2015-12-31 | Boston Scientific Scimed, Inc. | Compositions, devices, kits and methods for attaching stent-containing medical devices to tissue |
| KR101874265B1 (en) * | 2017-11-23 | 2018-07-03 | 주식회사 비앤디네트웍스 | Pharmaceutical Composition containing Photosensitizer for Periodontitis |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220041714A (en) | 2022-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cao et al. | Semiconducting polymer-based nanoparticles with strong absorbance in NIR-II window for in vivo photothermal therapy and photoacoustic imaging | |
| Cho et al. | Silica-coated metal chelating-melanin nanoparticles as a dual-modal contrast enhancement imaging and therapeutic agent | |
| Zhang et al. | Killing three birds with one stone: Near-infrared light triggered nitric oxide release for enhanced photodynamic and anti-inflammatory therapy in refractory keratitis | |
| Gravier et al. | Lipidots: competitive organic alternative to quantum dots for in vivo fluorescence imaging | |
| Li et al. | Diblock copolymer micelles deliver hydrophobic protoporphyrin IX for photodynamic therapy | |
| KR101267313B1 (en) | Photothermal ablation of cancer cells using organic nanoparticles | |
| Zhang et al. | Perylenediimide chromophore as an efficient photothermal agent for cancer therapy | |
| Qiao et al. | Self-assembled ROS-sensitive polymer–peptide therapeutics incorporating built-in reporters for evaluation of treatment efficacy | |
| ho Hong et al. | Indocyanine green-loaded hollow mesoporous silica nanoparticles as an activatable theranostic agent | |
| Bœuf et al. | Encapsulated Ruthenium (II) Complexes in Biocompatible Poly (d, l‐lactide‐co‐glycolide) Nanoparticles for Application in Photodynamic Therapy | |
| Lee et al. | A charge-switchable, four-armed polymeric photosensitizer for photodynamic cancer therapy | |
| US20210087463A1 (en) | Polymer nanoparticles for afterglow molecular imaging | |
| US9827313B2 (en) | Self-assembled pharmaceutical composition for photodynamic therapy | |
| KR102099516B1 (en) | NIR responsive cross-linked micelles, drug delivery carrier targeting cancer cell and method for preparing the same | |
| CN102740875A (en) | Nanoparticle carrier systems based on human serum albumin for photodynamic therapy | |
| Hou et al. | Silver-decorated, light-activatable polymeric antimicrobials for combined chemo-photodynamic therapy of drug-resistant bacterial infection | |
| Sun et al. | AgBiS 2-TPP nanocomposite for mitochondrial targeting photodynamic therapy, photothermal therapy and bio-imaging under 808 nm NIR laser irradiation | |
| Wang et al. | Tumor-targeting multi-shelled hollow nanospheres as drug loading platforms for imaging-guided combinational cancer therapy | |
| JP6425486B2 (en) | MRI contrast agent composition for contrasting cancer cells | |
| Fang et al. | Oxyhemoglobin-monitoring photodynamic theranostics with an 808 nm-excited upconversion optical nanoagent | |
| Zhang et al. | Near-infrared light-mediated and nitric oxide-supplied nanospheres for enhanced synergistic thermo-chemotherapy | |
| Varchi et al. | Core—Shell poly-methylmethacrylate nanoparticles as effective carriers of electrostatically loaded anionic porphyrin | |
| KR102621315B1 (en) | Composition for coating medical devices | |
| Zhang et al. | Versatile Preparation of Fluorescent Particles Based on Polyphosphazenes: From Micro‐to Nanoscale | |
| Husni et al. | Development and characterization of pH-responsive nanocarriers for chemo-photothermal combination therapy of acidic tumors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| AMND | Amendment | ||
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant |